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Abstract 
MLL1 is a histone-3 lysine-4 (H3K4) methyltransferase, which is misregulated in 
patients with leukemia and linked with tumorigenicity through upregulation of the target 
genes HoxA9 and Meis-1. Suppressing expression of these genes by targeting the 
catalytic activity of MLL1 may be a novel approach in cancer therapy. Methylation of 
H3K4 by MLL1 requires formation of a core complex consisting of MLL1, WDR5, 
RbBP5 and ASH2L. The interaction between MLL1 and WDR5 in this complex is 
essential for its catalytic activity and disruption of the MLL1-WDR5 interaction may 
provide significant therapeutic benefit to suppress target gene expression and thus 
tumorigenesis.  
In this study, the design of peptidomimetic inhibitors that can disrupt the 
interaction between MLL1 and WDR5 is presented. Starting from a 12mer peptide, the 
tripeptide -CO-ARA-NH- in MLL1 was identified as the minimal motif for binding to 
WDR5. Systematic modifications to the Ac-ARA-NH2 tripeptide were performed to 
elucidate the interaction of WDR5 with its ligands, and a number of peptidomimetic 
compounds with Ki < 1 nM for WDR5 were developed. These compounds were also 
demonstrated to effectively inhibit the catalytic activity of the reconstituted MLL1 core 
complex in vitro. Further modifications to improve cellular permeability of the 
peptidomimetic inhibitors led to design of MM-101 and MM-102, which have sub-
nanomolar binding affinities for WDR5. Crystal structures of MM-101 and MM-102 
provide insight for further development of inhibitors. MM-102 inhibits the interaction 
xvii 
 
between MLL1 and WDR5 in vitro, and reduces expression of HoxA9 and Meis-1 genes 
in MLL1-AF9 transduced bone marrow cells. These findings, together with the selective 
growth inhibition of leukemia cell lines with MLL1 fusion proteins upon treatment with 
MM-102, suggest that inhibitors targeting the MLL1-WDR5 interaction have a 
therapeutic potential in cancer therapy.  
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CHAPTER 1  
Introduction 
Mixed Lineage Leukemia 1 (MLL1) is a histone 3 lysine 4 (H3K4) 
methyltransferase, which plays pivotal role in hematopoiesis.1-3 H3K4 trimethylation by 
MLL1 upregulates transcription of certain target genes such as Hox genes, whose 
expression level is high in hematopoietic stem and progenitor cells and repressed with the 
differentiation to mature blood cells.4,5 Failure to repress Hox expression on the other 
hand, induces self-renewal and prevents differentiation that leads to leukemia.6 
Chromosomal rearrangements of the MLL1 gene are frequent in both acute 
myeloid leukemia (AML) and acute lymphoid leukemia (ALL).7,8 Although the exact 
mechanism for leukemic transformation with MLL1 fusion proteins is poorly understood, 
two MLL1 target genes, HoxA9 and Meis-1 are consistently upregulated with MLL1 
abnormalities.9 These genes have been shown to cooperate with each other to induce 
AML linking MLL1 with its tumorigenic properties.10 Therefore inhibiting MLL1 
function that would repress Hox genes expression might be a promising approach in 
leukemia therapy.   
In order to understand H3K4 methyltransferase activity of MLL1, a brief 
information to explain covalent histone modifications is necessary. 
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1.1 Histone Modifications 
 
Chromatin, the nuclear material that contains the genetic information, is 
composed of DNA and proteins, most of which are histones (H). The basic structural unit 
of chromatin is called nucleosome, where 146-147 base pair (bp) of DNA winds around 
an octameric histone core which consists of histone proteins (H2A, H2B, H3 and H4).  
 In the structural organization of the core (Figure 1) H3 and H4 form two distinct 
heterodimers, which then dimerize together. The resulting tetramer interacts with two 
corresponding heterodimers of H2A and H2B to form the nucleosome core.11,12 Linker 
DNA, which connects two nucleosome cores, completes the nucleosome structure. One 
Figure 1: Crystal structure of nucleosome (PDB:1KX5). 
H2A (cyan), H2B (yellow), H3 (Green), H4 (red), double stranded DNA (orange) 
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copy of H1 protein usually binds the dyad region of the nucleosome, adding additional 
DNA linker to the nucleosome core.13,14 
Histone proteins contain flexible, unstructured, highly basic and conserved N-
terminal tails, which are accessible for post-translational modifications. There are more 
than 100 different such sites in the histone proteins and at least nine types of 
modifications have been described to date. These include lysine acetylation, lysine & 
arginine methylation, serine & threonine phosphorylation, lysine ubiquitination, lysine 
sumoylation, arginine deamination, proline isomerization.15 Such covalent histone 
modifications play key roles in diverse functions such as transcription, repair and 
replication of DNA. Some of the modifications, for example acetylation, are believed to 
cause changes in steric and charge interactions between the DNA and histones, which 
result in dynamic changes in the chromatin architecture modifying accessibility to 
DNA.16 Methylation of histone lysine residues, which do not alter the overall charge, 
could repress or activate the transcription depending upon the modification site.17 
Phosphorylation, on the other hand, affects DNA repair and cell division.15,18 In general, 
post-translational histone modifications have diverse functions which depend on the type 
and site of the modification.  
1.2 Histone Lysine Methylation 
Figure 2: Lysine residue; from left to right, unsubstituted, mono-, di-, trimethylated lysine.
4 
 
The ε-nitrogen of lysine residues can be mono- (Me1), di- (Me2) or tri- (Me3) 
methylated (Figure 2). There are 6 sites in the histone core proteins that have been well-
characterized as targets for lysine methylation. Among these, H3K9, H3K27 and H4K20 
methylations are enriched in heterochromatin, the condensed form of chromatin, 
associated with transcriptional repression.19 H3K4, H3K36 and H3K79 methylations are 
enriched in euchromatin (the light stained and unfolded state of chromatin) and related to 
transcriptional activation.17,20 
1.3 H3K4 Methylation 
 
H3K4 trimethylation is an evolutionally conserved epigenetic mark for 
transcriptionally active chromatin in eukaryotes.17,21 Genes that are transcriptionally 
active are enriched with trimethylated H3K4 (H3K4Me3) near their transcription start 
sites.20,21 It is believed that H3K4Me3 is used as a recognition mark to recruit downstream 
modules. These effectors specifically recognize trimethylated H3K4 via chromodomains, 
tudor domain or PHD (Plant Homeo Domain) fingers.22 BPTF, the largest component of 
the remodeling complex NURF which is involved in Hox gene expression, has been 
shown to specifically recognize H3K4Me3. Another example is YNG1 (ING1 homolog 
1), a component of the NuA3 Histone Acetyl Transferase (HAT) complex, which 
acetylates H3K14. H3K4Me3 recognition by the NuA3 HAT complex has been proposed 
to induce H3K14 acetylation implying a direct relation between H3K4 methylation and 
H3K14 acetylation both of which are associated with transcriptionally active genes.23-25 
H3K4 methylation is a dynamic process; there are writers (histone 
methyltransferases) that add methyl groups on the lysine residue, and erasers 
(demethylases) that have been shown to remove the methyl groups on H3K4.26,27 The 
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first identified eraser was LSD1, which demethylates di- and mono-methylated lysine.28 
The subsequently described JMJC family proteins, including hSMCX, which is involved 
in transcriptional repression of target genes in the neurons, has been demonstrated to 
possess H3K4 demethylase activity for tri- or di-methylated lysine.29 
1.4 Organization and Function of the MLL1 Complex 
 
MLL1, with a conserved SET (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain 
as the catalytic subunit, functions within a protein complex.30 In human, there are six 
HMTase (Histone Methyltransferase) enzymes identified specific for H3K4. These are 
hSet1a (human Set 1a), hSet1b (human Set 1a) and MLL isoforms 1-4.31 MLL1, the most 
studied analog in this class, is a relatively large protein with 3969 amino acid residues.  It 
is cleaved by an aspartate protease, Taspase 1 in the cytosol, yielding a 320 kDa N-
terminal (MLL1N) and a 180 kDa C-terminal (MLL1C) as shown in Figure 3.32 It has 
Figure 3: Schematic representation of domain structure of MLL1 before and after the proteolytic cleavage. AT-
Hooks play role in binding to minor groove of DNA. CxxC domain binds to CpG rich DNA. Plant homodomain (PHD)
is involved in protein-protein interaction. Bromodomain (BD) is an acetylatd histone lysine recognition motif. FYRN
and FYRC domains in MLL1 mediate heterodimerization of MLL1N and MLL1C. Transactivation domain (TAD) binds
CBP, which might acetylate H3 and H4 on Hox genes. SET domain is the catalytic domain where N-terminal of H3
binds and gets methylated. 
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been shown that MLL1N and MLL1C associate non-covalently with each other to form a 
heterodimer through their FYRN and FYRC domains, respectively, and translocate to the 
nucleus where they maintain the association and form the MLL1 complex.32 
MLL1N associates with regulatory elements such as Menin and HCFs, while 
MLL1C forms a catalytically active “core complex” with WDR5 (WD repeat domain 5 
protein), ASH2L (Absent, Small, or Homeotic-2-Like) and RbBP5 (Retinoblastoma 
Binding Protein 5), as shown in Figure 4.30,33 MLL1C has minimal catalytic activity and 
requires all the core complex members for a fully functional activity.33 Stable interaction 
of RbBP5 and ASH2L with MLL1C is required for the catalytic activity, and WDR5 
maintains the stability of the core complex by forming a bridge between MLL1 and 
RbBP5.34 In addition to the core components, Menin is believed to direct the complex to 
the target genes, but the role of HCFs and DPY30 in MLL1 complex is obscure.35 
 
The best well known targets for MLL1 are the Hox genes. Organized in 4 clusters 
(A-D) located on chromosomes 7, 17, 12 and 2, Hox genes encode for a class of 
homeodomain transcriptional factors that regulate cell proliferation and differentiation 
during embryonic development as well as proper hematopoiesis in adults.1,36-38 Hox 
proteins use their homeodomain (helix-turn-helix motif) to interact with major groove in 
Figure 4: Structural organization and role of MLL1 complex.
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their target genes and require a co-factor, PBX1 or Meis-1, to increase their binding 
affinity to DNA.38 The direct downstream targets for Hox proteins in hematopoiesis are 
not clear but HoxA9 is preferentially expressed in hematopoietic stem cells (HCS) and 
plays an essential role in self-renewal while blocking differentiation of HCS to mature 
blood cells.5,39 
1.5 Leukemic Transformation with MLL1 Fusion Proteins 
 
MLL1 was initially identified as the common target for 11q23 chromosomal 
translocations in acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).40 
MLL1 translocation is a hallmark of infant ALL and observed in 80% of cases with 
relatively poor prognosis and survival rate.41,42 It is also common in childhood AML and 
chemotherapy-induced leukemia. Patients previously treated with topoisomerase II 
inhibitors frequently develop secondary AML and are found to have chimeric MLL1 
proteins.43,44 In these proteins, the C-terminal region of MLL1, including PHD domains, 
is replaced with C-terminal of variety of cytosolic and nuclear proteins.45,46 There are 
more than seventy fusion partners identified for MLL1, only a subset of which is 
associated with aggressive leukemia. The MLL1-AF4, MLL1-AF9, MLL1-AF10, MLL1-
ENL and MLL1-ELL fusion proteins account for the majority of cases with poor 
prognosis.8 Although the exact mechanism for leukemic transformation with chimeric 
MLL1 proteins is poorly understood, certain MLL1 target genes, including HoxA9 and 
Meis-1 are consistently upregulated with MLL1 abnormalities and required for leukemic 
transformation linking MLL1 fusion proteins with their tumorigenic properties.10,47-49 
HoxA9 depletion in MLL1-rearranged leukemia significantly reduces the cell viability 
and induces apoptosis. MLL1-ENL transduced bone marrow (BM) transplantation 
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induces AML in vivo in the presence of HoxA9 expression.50 Enforced overexpression of 
HoxA9 can induce AML with a long latency, but co-expression with Meis-1 leads to rapid 
onset of the leukemia suggesting that both HoxA9 and Meis-1 play a central role for the 
leukemic transformation with MLL1 fusion proteins.51 
It is unclear how the chimeric MLL1 proteins can upregulate expression of wild-
type MLL1 target genes (e.g. HoxA9 and Meis-1) while they lack H3K4 methylating 
activity. Recent studies suggest that the wild-type MLL1 is also involved in the 
mechanism of leukemic transformation of MLL1 fusion proteins.52,53 It has been shown 
that both wild-type MLL1 complex and MLL1-AF9 fusion proteins are recruited to the 
HoxA9 locus and required for leukemogenesis, as represented in Figure 5. In the absence 
of wild-type MLL1 allele, the MLL1-AF9 fusion protein is unable to develop leukemia in 
mice.53 Therefore, targeting the activity of wild-type MLL1 represents a novel approach 
to develop new therapies for acute leukemia. 
 
 
MLL1C
RbBP5
WDR5
Ash2L
NH2
(wild-type MLL1 Complex)
MLL1N
Menin
H3
(MLL1 Core Complex)
N
H3K4Me3
H3
Me
Me
Me
+
H3K4
transcriptional
activation
Induce self renewal
Prevent differentiation
Leukemogenesis
HoxA9
MLL1 Fusion Protein
fusion
partner
Menin
Meis 1
HoxA9
Meis 1
Figure 5: Schematic representation of leukemic transformation with MLL1 fusion proteins and wild-type MLL1
complex. 
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1.6 Targeting the MLL1-WDR5 Interaction 
 
A conserved Arg residue (R3765) in MLL1 mediates the interaction of MLL1 
with WDR5, and Ala mutation of this residue abolishes H3K4 methylation of the core 
complex in vitro.54 WDR5 knockdown in HEK 293 cells results in a decrease in H3K4 
trimethylation at the HoxA9 and HoxC8 gene promoters.55 Therefore, inhibition of the 
MLL1-WDR5 interaction might be a successful strategy with which to target MLL1 
activity in leukemia.  
WDR5 contains an interior cavity (Figure 6a) and the beginning and the end of 
this cavity are sites where protein-protein interactions occur.56,57 A shallow hydrophobic 
pocket, near the bottom binding pocket (Figure 6c) is used to interact with RbBP5.58 It is 
not known if the bottom binding pocket is essential to the MLL1 complex. Initially, 
WDR5 had been shown to interact with the N-terminal tail of H3 using top binding 
pocket, arginine binding pocket, and it was therefore believed to function by presenting 
K4 to the catalytic SET domain for methylation.57,59 Subsequently, two separate groups 
showed that the conserved region at the N-SET domain of MLL1 binds to WDR5 with a 
higher binding affinity than the H3 peptide.54,60 Both H3 and MLL1 peptides use an ARX 
motif to bind WDR5 which explains the similar binding modes. A detailed analysis of 
both interactions is presented in Chapter 3. 
A 12 aa sequence (residues 3762-3773, GSARAEVHLRKS) from MLL1, named 
WIN (WDR5 Interacting motif) by Patel et al., has been shown to interact with WDR5 as 
shown in Figure 6 and can dissociate complexes formed between MLL1-WDR5 and 
MLL1-WDR5-RbBP5-ASH2L.54,61 The WIN peptide therefore represents a promising 
starting point for the design of inhibitors of the MLL1-WDR5 interaction.   
10 
 
 
The design of peptidomimetic inhibitors of MLL1-WDR5 interaction is presented 
in this study. Initially, a competitive binding assay was developed to test the affinities of 
inhibitors for WDR5. Next, the minimal motif in MLL1 for WDR5 binding was 
determined by a truncation study using the WIN peptide. Further modifications to 
improve binding affinity led to the design of peptidomimetics that bind to WDR5 with 
sub-nanomolar Ki and which can efficiently inhibit the catalytic activity of the MLL1 
Figure 6: Top and bottom binding pockets of WDR5 (PDB:3EG6). Top (Arginine) binding pocket is ligated with
MLL1 WIN peptide (C-terminal residues RKS are not resolved). 
b) c) 
a) 
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core complex in vitro. These inhibitors however have undetectable permeability in an in 
vitro permeability assay and efforts to improve cellular permeability yielded two lead 
compounds, MM-101 and MM-102, both of which can inhibit MLL1C-WDR5 interaction 
in vitro. MM-102 reduces HoxA9 and Meis-1 expression in MLL1-AF9 transduced bone 
marrow cells and shows specificity to inhibit growth of leukemia cell lines with MLL1 
fusion proteins, suggesting that targeting MLL1-WDR5 interaction could be a potential 
strategy in acute leukemia with MLL1 fusion proteins. The crystal structures of both 
MM-101 and MM-102 complexed with WDR5 confirm the design strategy and provide 
insight for further inhibitor design.   
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CHAPTER 2  
Development of FP-Based Binding Assay 
 
The quantitative Fluorescent Polarization (FP)-based assay is valuable for 
accurate evaluation of the binding affinities of the compounds under investigation. The 
FP assay is based on the principle that when a compound or tracer containing a 
fluorescent chromophore (tracer) is exposed to polarized light, it absorbs the energy and 
emits high level of polarized fluorescence if it is stationary (Figure 7). Thus when the 
tracer is bound to a protein, a high level of emitted fluorescence measurement will be 
observed. If, on the other hand, binding inhibitors are present the tracer will be free and 
mobile in solution, and the level of emitted fluorescence will be decreased.  
 
 
Figure 7: Schematic representation of principle of FP-based competitive binding assay. 
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2.1 Design and Optimization of Fluorescently Tagged Peptides for Assay 
Development 
 
Initially two tracers WIN-FAM-1 and WIN-FAM-2, tagged with 5-
carboxyfluorescein (5-FAM, Figure 8) were synthesized using the WIN sequence with 
two different linkers, as shown in Table 1. The 5-carboxyfluorescein was introduced to 
the side chain of C-terminal lysine residue as described in the experimental section 
(Appendix A). These two tracers were found to have similar Kd values and dynamic 
ranges in the WDR5 saturation experiments (Table 1 and Figure 9). 
 
Table 1: The 5-FAM labeled tracers designed in this study. 
Ac-Amino acid sequence-Linker-K(5-FAM)-NH2 
Tracer Name Amino acid sequence Linker Kd ± SD (µM)
WIN-FAM-1 GSARAEVHLRKS βA-βA-βA* 0.86 ± 0.15 
WIN-FAM-2 GSARAEVHLRKS Ahx-Ahx** 0.94 ± 0.15 
10mer-Ala-FAM      ARAEVHLRKS Ahx-Ahx 0.014 ± 0.002 
10mer-Thr-FAM       ARTEVHLRKS Ahx-Ahx 0.001 ± 0.0003 
*βA = Beta alanine   **Ahx = 6-Amino hexanoic acid 
 
An FP-based competitive binding assay was developed with WIN-FAM-1, and 
screening of the designed MLL1 peptides with this initial assay revealed that removal of 
Gly and Ser residues from N-terminal of the WIN peptide improves the binding affinity 
significantly, which led to the design of 10mer-Ala-FAM (Table 1). Screening of 
designed H3 peptides also suggested that substitution of Ala3 with Thr in MLL1 peptides 
Figure 8: Structure of 5-Carboxy Fluorescein.
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can further improve the binding affinity to WDR5, and this led to the design of 10mer-
Thr-FAM (Table 1). Saturation experiments showed that while 10mer-Ala-FAM and 
10mer-Thr-FAM have similar dynamic ranges (ΔmP), both peptides have higher 
affinities for WDR5 than WIN-FAM-1 and WIN-FAM-2, and the affinity of 10mer-Thr-
FAM is 10 times higher than that of 10mer-Ala-FAM (Table 1 and Figure 9a). 
2.2 Development and Optimization of Competitive Binding Assay Conditions 
With the highest binding affinity for WDR5 in the saturation experiments (Figure 
9a) 10mer-Thr-FAM was selected for development of an optimized FP-based competitive 
binding assay. First the minimum concentration of 10mer-Thr-FAM necessary to produce 
a total fluorescence intensity of 100,000 units was determined in the competitive binding 
assay. It was found that this fluorescence intensity was achieved at the concentrations of 
0.6 nM or higher, and accordingly, this was selected as the tracer concentration for 
further evaluations of the assay conditions. Next the millipolarization (mP) values were 
measured at different time points in order to determine equilibrium duration and stability. 
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Figure 9: Saturation binding experiments with 0.6 nM of the tracers (a) WIN-FAM-1, WIN-FAM-2, 10mer-Thr-
FAM and 10mer-Ala-FAM were titrated with WDR5 separately. (b) Stability of the saturation binding experiment with
10mer-Thr-FAM over 24 h. mP values are measured at the indicated time points. 
15 
 
The equilibrium between the tracer and protein was reached at 2 h and was stable for over 
24 h (Figure 9b). 
Higher protein concentrations can increase the dynamic range of the assay, but for 
the sake of assay sensitivity and accuracy, the protein concentration should not exceed 
the linear range of the saturation curve.62 Accordingly, the optimal protein concentration 
for the competitive assay was investigated. WDR5 (2, 3, and 4 nM) with 0.6 nM of 
10mer-Thr-FAM was evaluated in competitive binding assays and the binding affinities 
of Ac-10mer (Table 3) were determined under these assay conditions. Although very 
similar IC50 values were obtained with these three WDR5 protein concentrations, the 
dynamic range increased from 31 to 40 mP when the protein concentration was increased 
from 2 to 4 nM and. 4 nM was chosen as the optimal WDR5 protein concentration 
together with 0.6 nM of 10mer-Thr-FAM tracer in the competitive binding assay that was 
used in this study for determination of the IC50 values of the peptides. All Ki values were 
calculated using the equation and the associated software developed previously for FP-
based assays.62 Representative examples of competitive binding curves are shown in 
Figure 10 for peptides with varying binding affinities to WDR5. The structures of the 
peptides are discussed in Chapter 3.  
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Figure 10: Competitive binding curves for Ac-10mer, Ac-3mer, WIN and H2N-10mer as determined using a
fluorescence polarization based assay. 
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CHAPTER 3  
Analysis of the MLL1 and Histone 3 (H3) Peptides Binding to WDR5 
3.1 Determination of the Minimal Motif in MLL1 for High-Affinity Binding to 
WDR5 
 
The MLL1 peptide containing the WIN sequence was shown to bind to WDR5 
with Kd = 0.12 μM.54 To identify the residues critical to the high-affinity binding of the 
WIN peptide to WDR5, the WIN-peptide residues, whose numbering is given in Table 2, 
were systematically deleted from either its N-terminal or C-terminal end. Numbering 
assigned here allows comparison of the residues in WIN and Histone 3 (H3) two 
peptides. 
Table 2: Sequence of WIN peptide and N-terminal of H3 peptide. Residues 1-10 in H3 and 3762-3773 in MLL1 
are shown. 
WIN G S A R A E V H L R K S 
N-term of H3   A R T K Q T A R K S 
Numbering used here -2 -1 1 2 3 4 5 6 7 8 9 10 
 
All the peptides produced, unless stated otherwise, were acetylated at the N-
terminus and capped with an amide at the C-terminus. Solid phase syntheses of all the 
analogs are described in Appendix A. The binding affinity of each peptide to WDR5 was 
measured with the optimized FP-based competitive binding assay (described in Chapter 
2). 
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Table 3: Binding affinities of truncated MLL1 peptides to WDR5. 
Peptide Formula IC50± SD (µM) Ki± SD (µM) 
WIN Ac-GSARAEVHLRKS-NH2 0.75 ± 0.10 0.16 ± 0.02 
Ac-11mer    Ac-SARAEVHLRKS-NH2 1.04 ± 0.14 0.20 ± 0.03 
Ac-10mer      Ac-ARAEVHLRKS-NH2 0.020 ± 0.004 0.003 ± 0.001 
H2N-11mer  H2N-SARAEVHLRKS-NH2 0.08 ± 0.01 0.020 ± 0.002 
Ac-9mer         Ac-RAEVHLRKS-NH2 29 ± 4 6.30 ± 0.80 
Ac-7mer       Ac-ARAEVHL-NH2 0.16 ± 0.03 0.03 ± 0.01 
Ac-6mer       Ac-ARAEVH-NH2 0.40 ± 0.10 0.09 ± 0.02 
Ac-5mer       Ac-ARAEV-NH2 0.75 ± 0.10 0.16 ± 0.03 
Ac-4mer       Ac-ARAE-NH2 0.40 ± 0.05 0.08 ± 0.01 
Ac-3mer       Ac-ARA-NH2 0.54 ± 0.03 0.12 ± 0.01 
Ac-2mer        Ac-AR-NH2 125 ± 6 27 ± 1 
 
As can be seen in Table 3, the 12-residue WIN peptide has a Ki value of 0.16 μM, 
similar to the reported values.54,60 Removal of the Gly from the -2 position does not affect 
the binding significantly. Interestingly, further deletion of Ser from the -1 position in the 
11-residue peptide results in a highly potent 10-residue peptide (Ac-10mer), with Ki = 3 
nM, 50 times that of the WIN peptide. The N-terminal acetyl group in Ac-11mer was 
found to be detrimental to its binding to WDR5 and the H2N-11mer peptide with a free 
N-terminus is 10 times more potent than Ac-11mer. Further deletion of Ala1 from Ac-
10mer, giving Ac-9mer, decreases the binding affinity by a factor of 1500. 
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Truncation of the sequence from the C-terminus of Ac-10mer was investigated 
next. Simultaneous deletion of Arg8, Lys9, and Ser10 residues unresolved in the co-
crystal structure of WIN-WDR5 complex,61 led to Ac-7mer, which has a 10-fold lower 
binding affinity than Ac-10mer. Further stepwise deletions from the C-terminus 
generated Ac-6mer, Ac-5mer, Ac-4mer, and Ac-3mer, all of which have binding 
affinities similar to the 12-residue WIN peptide. However, removal of Ala3 from the Ac-
3mer peptide results in >200-fold loss of binding affinity to WDR5. It is concluded 
consequently that the Ac-3mer (Ac-ARA-NH2) is the shortest MLL1 peptide to achieve 
high-affinity binding to WDR5. 
3.2 Role of Two Intramolecular Hydrogen Bonds in MLL1 Peptides for High-
Affinity Binding to WDR5 
 
In the crystal structure of the WDR5-WIN complex, two intramolecular hydrogen 
bonds can be seen in the main chain of the WIN peptide.61 The first is between the Ser 
carbonyl oxygen at the -1 position and the amide proton of Ala3 and the second is 
between the Ala1 carbonyl oxygen and the Glu4 amide proton. These intramolecular 
hydrogen bonds cause the peptide to adopt a 310-helical secondary structure and possibly 
contribute to the affinity of the WIN peptide for WDR5. Ac-ARA-NH2 with a binding 
affinity similar to that of the 12mer WIN peptide, maintains these two intramolecular 
hydrogen bonds and thus was used to explore the modifications (Figure 11a and 11b) 
described in this part of the study.  
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First, hydrogen bond 1 was eliminated by removing the acetyl group from Ala1 or 
by methylating the Ala3 nitrogen. Removal of the acetyl group from the N-terminal Ala1 
of the Ac-3mer peptide yields H2N-3mer, which does not bind to WDR5 up to the 
concentrations tested (Table 4). To further confirm the critical importance of this 
hydrogen bond, the acetyl group from the most potent Ac-10mer peptide was removed, 
leading to a >1500-fold decrease in binding affinity. A similar reduction in binding 
Figure 11: Intramolecular hydrogen bonds. 
(a) Hydrogen bonds 1 and 2 and the atoms involved in Ac-ARA-NH2 are shown. 
(b) Ac-ARA-NH2 and, 
(c) H2N-ARA-NH2, modeled in the Arg binding pocket of WDR5 based on PDB entry 3EG6. The 
intramolecular hydrogen bonds are shown as yellow dots. Carbon atoms are shown in cyan in the 
peptide and grey in WDR5. The nitrogen and oxygen atoms are colored in blue and red, 
respectively. 
2 
1 
2 
20 
 
affinity was observed when the N-terminal acetyl group was removed from the Ac-7mer, 
Ac-6mer, and Ac-5mer peptides. Methylation of the Ala3 nitrogen, giving peptide Δ1, in 
which hydrogen bond 1 is destroyed, led to a complete loss of binding to WDR5.  
Table 4: Removal of intramolecular hydrogen bonds in Ac-ARA-NH2. 
Peptide Formula IC50±SD (µM) Ki ±SD (µM) 
Ac-10mer    Ac-ARAEVHLRKS-NH2   0.020 ± 0.004 0.003 ± 0.001 
H2N-10mer H2N-ARAEVHLRKS-NH2 34 ± 3 7.30 ± 0.70 
Ac-3mer Ac-ARA-NH2   0.54 ± 0.03 0.12 ± 0.01 
H2N-3mer  H2N-ARA-NH2 > 300 > 50 
CHO-3mer CHO-ARA-NH2 14.9 ± 1.4 3.20 ± 0.30 
Δ1 Ac-AR-(N-Me)A-NH2 > 300 > 50 
Δ2a Ac-ARA-CONHMe   0.70 ± 0.14 0.15 ± 0.03 
Δ2b Ac-ARA-CONMe2 30 ± 5 6.50 ± 1.20 
Δ2c Ac-ARA-COOCH3   7.30 ± 0.80 1.60 ± 0.20 
 
Next the methyl group from the N-terminal acetyl was removed, yielding CHO-
ARA-NH2 peptide, in order to explore the contribution of the carbonyl in the absence of 
methyl. Replacement of the acetyl by a formyl group decreases the binding affinity by a 
factor of 25, suggesting that the methyl group in the N-terminal acetyl contributes to the 
increase in binding affinity, albeit to a smaller extent. Together, these data show that 
hydrogen bond 1 plays a vital role in maintaining the high binding affinities of the potent 
MLL1 peptides to WDR5, presumably through stabilization of the bound conformation. 
To perturb hydrogen bond 2, first the C-terminal amide in Ac-3mer (Table 3) was mono- 
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or dimethylated. The monomethylated derivative, peptide Δ2a, shown by modeling to be 
capable of maintaining hydrogen bond 2 in its bound conformation has Ki = 0.15 μM, 
similar to that of Ac-3mer, but the dimethylated derivative (peptide Δ2b) is 50 times less 
potent than Ac-3mer. Replacement of the C-terminal amide group with a methyl ester 
gave peptide Δ2c, which is 10 times less potent than Ac-3mer. These data indicate that 
while hydrogen bond 2 makes an important contribution to the binding affinity of Ac-
3mer, increasing it by perhaps an order of magnitude, it is less critical than hydrogen 
bond 1. 
Molecular dynamics (MD) simulations of Ac-ARA-NH2 and H2N-ARA-NH2 
peptides were performed to further investigate hydrogen bonds 1 and 2. As shown in 
Figure 12a, the probability associated with the distance between the nitrogen and oxygen 
atoms in hydrogen bond 1 in Ac-ARA-NH2 has a narrow distribution and a maximum 
around 3 Å, indicating a very stable and strong hydrogen bond. In comparison, the 
probability for the distance between the nitrogen and oxygen atoms in hydrogen bond 2 
in Ac-ARA-NH2 while also having a maximum around 3 Å has a broad distribution 
suggesting that hydrogen bond 2 is the weaker of the two hydrogen bonds. The 
Figure 12: MD simulations of (a) Ac-ARA-NH2 and, (b) H2N-ARA-NH2 peptides in Amber comparing
probability of intramolecular hydrogen bond formation and the length of the bonds. 
a) b) 
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probability for the distance between the nitrogen and oxygen atoms in the deacetylated 
peptide NH2-ARA-NH2 (Figure 12b) has a narrow distribution but a maximum around 7 
Å, indicating the absence of a hydrogen bond. Thus these simulations suggest that 
hydrogen bond 1 is stronger than hydrogen bond 2 and is also more critical in 
maintaining the proper bound conformation of the peptide for interaction with WDR5 and 
it was concluded that -CO-ARA-NH- is the minimal motif within the WIN peptide for 
high affinity binding to WDR5. 
3.3 Binding of H3 Peptides to WDR5 
 
While H3 and MLL1 peptides have similar binding modes to WDR5, the H3 
peptides show much weaker affinities than MLL1 peptides.63 The H3 peptides have an 
ART binding motif in place of the ARA binding motif in the MLL1 peptides but possess 
a free amino group at the Ala1 residue. To investigate if this free amino group is 
responsible for their weaker binding affinities, H3-3mer and H3-10mer peptides were 
acetylated (Table 5). In both cases, acetylation of this free amino group increases binding 
affinity to WDR5 significantly (1,500 times for Ac-H3-3mer and >10,000 times for Ac-
H3-10mer). 
The Ac-H3-3mer and Ac-H3-10mer peptides have Ki values with WDR5 of 20 
nM and <1 nM, respectively, and are both more potent than the corresponding MLL1 
peptides Ac-3mer and Ac-10mer (Tables 4 and 5). These data show that the primary 
feature underlying the weaker binding affinities of H3 peptides to WDR5 is the free 
amino group of Ala1 and the resulting absence of intramolecular hydrogen bond 1.  
Next, the binding of H3-10mer to WDR5 was examined to learn if methylation of 
Lys4 (K4) significantly changes this binding. Mono-, di-, or tri-methylation of K4 led to 
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no significant difference in the binding affinity to WDR5 compared to that of H3-10mer 
(Table 5). This is consistent with previous experiments using isothermal titration curve 
measurements.59 
 
Table 5: H3 binding to WDR5. 
Peptide Formula 
IC50± SD 
(µM) 
Ki ± SD 
(µM) 
H3-10mer H2N-ARTKQTARKS-NH2 70 ± 6 15.1 ± 1.3 
Ac-H3-10mer    Ac-ARTKQTARKS-NH2 0.006 ± 0.002  0.001 
H3-3mer  H2N-ART-NH2 127 ± 12 27.3 ± 2.5 
Ac-H3-3mer     Ac-ART-NH2 0.08 ± 0.01 0.02 ± 0.001
H3-10mer-K4Me   H2N-ARTK(Me)QTARKS-NH2 69 ± 7 15.0 ± 1.6 
H3-10mer-K4Me2    H2N-ARTK(Me2)QTARKS-NH2 42 ± 6 9.0 ± 1.3 
H3-10mer-K4Me3    H2N-ARTK(Me3)QTARKS-NH2 73 ± 6 15.6 ± 1.2 
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3.4 Conclusion 
 
To facilitate the design of small-molecule inhibitors of the MLL1-WDR5 
interaction, critical elements required for high-affinity binding to WDR5 and the 
structural features responsible for the large difference in binding affinities of the MLL1 
and H3 peptides to WDR5 were investigated. Through systematic analysis of peptides 
derived from the 12mer MLL1 WIN peptide, the minimal binding motif in the MLL1 
peptides required for high binding affinity to WDR5 was found to be -CO-ARA-NH-. 
The tripeptide Ac-ARA-NH2, containing this minimal binding motif, has Ki = 0.12 μM 
with WDR5 in the FP-based competitive binding assay, essentially the same as that of the 
12-residue WIN peptide (Ki = 0.16 μM) determined under the same assay conditions.  
The residues RKS at the C-terminus of the WIN peptide, which were not resolved 
in the crystal structure of the WIN peptide complexed with WDR5,51 appear to enhance 
the binding affinity to WDR5 by a factor of 10. The most potent peptide derived from the 
MLL1 peptide sequence is Ac-10mer (Ac-ARAEVHLRKS) which, with Ki = 3 nM, is 50 
times more potent than the original 12-residue WIN peptide. 
A dramatic increase was observed in binding affinities of the MLL1 peptides 
upon N-terminal acetylation of Ala1, which results in formation of the intramolecular 
hydrogen bond 1. Examination of Ac-ARA-NH2 as the template molecule showed that 
the hydrogen bond 1 is essential for this high-affinity binding to WDR5 and in addition, 
MD simulations suggest that hydrogen bond 1 is required for the stability of hydrogen 
bond 2. Disruption of hydrogen bond 2 while maintaining hydrogen bond 1 decreases the 
binding affinity by only 10-fold. The methyl group of the N-terminal acetyl also 
contributes to the binding affinity and it was concluded that both of the intramolecular 
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hydrogen bonds and the methyl of the acetyl group contribute to the improvement in 
binding affinity upon N-terminal acetylation. 
Although H3 peptides contain an ART motif, corresponding to the ARA motif in 
the MLL1-based peptides, they have a free amino group at their N-terminus and are thus 
incapable of forming hydrogen bond 1 that is observed in the MLL1 peptides. It was 
hypothesized that the absence of hydrogen bond 1 in the H3 peptides underlies their 
much reduced binding affinities to WDR5 compared to the MLL1 peptides. The wild-
type H3 peptide (ARTKQTARKS), with a free N-terminal amino group, has Ki = 15 μM 
to WDR5 in the FP-based competitive binding assay, but introduction of an acetyl group 
at its N-terminus to establish the missing intramolecular hydrogen bond 1 improves the 
binding affinity by a factor of >10,000. Furthermore, Ac-ART-NH2 binds to WDR5 with 
Ki = 20 nM and is 6 times more potent than Ac-ARA-NH2 whose design is based upon 
the MLL1 peptide sequence. 
Acetylation of the N-terminal amino group of the MLL1 peptides and the 3mer 
H3 peptide (ART), improves their binding affinities to WDR5 by a factor of ~1,500, but 
>10,000 times improvement is observed upon the acetylation of H3-10mer. Ac-
ARTKQTA (Ac-H3-7mer) similarly shows a >10,000 increase in binding affinity to 
WDR5 upon N-terminal acetylation. Therefore, it is likely that one or more of the 
residues (KQTA) in Ac-H3-10mer or Ac-H3-7mer, which are not present in the MLL1 
peptides and Ac-ART, contribute to the further increase in binding affinity. 
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CHAPTER 4  
SAR Studies of Ligand-WDR5 Interaction 
The truncation study described in Chapter 3 revealed that -CO-ARA-NH- motif 
within MLL1 is necessary and sufficient for high-affinity interaction with WDR5.64 The 
Ac-ARA-NH2 tripeptide (Figure 2), which retains this minimal motif, was identified as a 
promising lead structure for further optimization. In this part of the study extensive 
modifications of Ac-ARA-NH2 were performed in order to define the detailed structure-
activity relationship for binding to WRD5. 
4.1 Determination of Favorable Residues for Binding to WDR5 at Ala1, Arg2 and 
Ala3 Positions in Ac-ARA-NH2 
 
Based upon the crystal structure of MLL1 peptide in a complex with WDR5, a 
binding model of Ac-ARA-NH2 in a complex with WDR5 was predicted (Figure 13a). 
Analysis of this binding model suggests that the key interactions between Ac-ARA-NH2 
and WDR5 may be broadly divided into five sub-sites (S1-S5 in Figure 13a-b). The 
methyl group of Ala1 interacts with a small binding pocket (S1) formed by Y131 and 
F149 (Figure 13b). To probe this pocket, Ala1 was replaced with residues of different 
sizes, shapes and hydrophobicities (Table 6). Replacement of Ala1 with Gly (1a) 
decreases the binding affinity by a factor of >100. In contrast, substitution of Ala1 with 
either 2-aminobutyric acid (2-Abu) (1b) or Val (1c) improves binding affinity by a factor 
of 2. However, residues with a side chain larger than the isopropyl in Val decrease the 
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binding affinity significantly, as evident from the much reduced binding affinities of 1e 
and 1f.  
 
Residues with a polar side chain in this position such as Ser (1i) and Thr (1j) in 
this position also weaken the binding by 5 times as compared to Ala and by 
approximately 10 times as compared to Val and 2-Abu. A hydrophobic aromatic residue 
Phe (1h) or a polar aromatic residue His (1g) decreases the binding by 3-6 times as 
compared to Ala. Hence, the most favorable residues for binding in the S1 pocket are 
either 2-Abu or Val. 
 
Figure 13: (a) Interaction of WDR5 with Ac-ARA-NH2 peptide in the predicted binding model. (b) Binding
pockets (S1-S5) in WDR5 and their interaction with Ac-ARA-NH2.
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Table 6: Binding affinities of Ac-ARA-NH2 analogs designed to investigate WDR5-ligand interaction through the 
S1 pocket. 
 
Peptide R1 IC50 ± SD (µM) Ki ± SD (µM) 
ARA  0.54 ± 0.03  0.12 ± 0.01 
1a GRA   77.4 ± 13.2   16.7 ± 2.8 
1b AbuRA 
 
0.28 ± 0.02 0.060 ± 0.001 
1c VRA 
 
0.24 ± 0.03 0.050 ± 0.005 
1d CRA 
 
1.83 ± 0.30 0.4 ± 0.6 
1e LRA 
 
10.8 ± 0.4 2.3 ± 0.3 
1f ChgRA 
 
8.7 ± 0.6 1.9 ± 0.1 
1g HRA 
 
1.7 ± 0.3 0.40 ± 0.03 
1h FRA 
 
3.1 ± 0.3 0.7 ± 0.1 
1i SRA 
 
2.9 ± 0.6 0.6 ± 0.1 
1j TRA 
 
2.9 ± 0.4 0.6 ± 0.1 
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Next Arg2 was modified. In the crystal structures of WDR5 bound to either 
MLL1 or H3 peptides60,65 and in the predicted binding model of Ac-ARA-NH2 with 
WRD5, the Arg side chain inserts into a deep cavity in WDR5 and has extensive 
interactions with the S2 channel of WDR5 (Figure 13a-b). The guanidino group in Arg 
forms -cation interactions with F133 and F263 via its two ω-nitrogen atoms. These two 
ω-nitrogen atoms also form hydrogen bonds directly with the backbone carbonyl groups 
of F133 and C261 and, via two water molecules, with S175 and S218. The δ-nitrogen in 
Arg forms a hydrogen bond with the backbone carbonyl group of S91. There are also 
hydrophobic contacts between the hydrophobic portion in the side chain of Arg2 and 
I305 side chain. Since the S2 channel is narrow, only a number of residues with linear 
side chains to probe this site were selected (Table 7).  
Table 7: Binding affinities of Ac-ARA-NH2 analogs designed to investigate WDR5-ligand interaction through 
the S2 channel. 
 
 
 
 
 
 
 
Peptide R2 IC50 ± SD (µM) Ki ± SD (µM) 
ARA 0.54 ± 0.03 0.12 ± 0.01 
2a ANleA > 300 > 65 
2b AOrnA > 300 > 65 
2c AKA > 300 > 65 
2d ACitA > 300 > 65 
Nle (Nor-leucine), Orn (Ornithine), Cit (citrulline) 
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Replacement of the guanidino of Arg2 with a methyl group (2a) or removal of the 
amidine portion of guanidino group (2b) leads to complete loss of binding. Replacement 
of Arg2 with Lys (2c) yields another inactive compound. Finally, replacement of the Arg 
guanidino with urea yields 2d, which also fails to bind to WDR5. These results clearly 
show that the side chain of Arg2 is essential for binding to WDR5, consistent with the 
extensive interactions between Arg2 and WDR5 observed in the predicted binding model. 
Next, Ala3 was modified. The Ala3 side chain is projected to a hemispherical 
hydrophobic S4 pocket formed mainly by side chains of A47 and L321 in WDR5 (Figure 
13a-b). Replacement of the methyl in Ala3 with hydrogen (3a) decreases the binding by 
>10-fold. Changing this methyl group to ethyl (3b), however, improves the binding 
affinity by a factor of 20.  
Further increase in the size of the ethyl to isopropyl (3c) reduces the binding 
affinity 3-fold as compared to 3b, although 3c is still 5 times more potent than the ARA 
peptide. Peptides with a side chain larger than isopropyl, for example ARL (3e), ARChg 
(3f) and ARF (3g) all have much weaker affinities than the ARA peptide. Replacement of 
Ala3 with Cys (3d) or Thr (3i) leads to 5-fold enhancement in binding affinity, similar to 
that achieved by Val. Finally, replacement of Ala3 with Ser (3h) reduces the binding by 3 
times as compared to ARA, but Glu at this position (3j) decreases the binding by >100 
times. 
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Table 8: Binding affinities of Ac-ARA-NH2 analogs designed to investigate WDR5-ligand interaction through S4 
pocket. 
 
Peptide R3 IC50 ± SD (µM) Ki ± SD (µM) 
ARA  0.54 ± 0.03 0.12 ± 0.01 
3a ARG  10.3 ± 1.2 2.2 ± 0.3 
3b ARAbu 
 
0.030 ±  0.008 0.006 ± 0.002 
3c ARV 
 
0.11 ± 0.02 0.020 ± 0.003 
3d ARC 
 
0.08 ± 0.01 0.020 ± 0.003 
3e ARL 
 
34 ± 6 7.3 ± 1.2 
3f ARChg 
 
280 ± 70 61 ± 16 
3g ARF 
 
280 ± 40 60 ±  8 
3h ARS 
 
1.8 ± 0.1 0.40 ± 0.07 
3i ART 
 
0.08 ± 0.01 0.020 ± 0.001 
3j ARE 
 
> 100 > 20 
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4.2 Further Modifications Using Constrained Hydrophobic Side Chains to Target 
S1 and S4 Pockets 
 
The modifications described above showed that small hydrophobic groups at the 
Ala1 and Ala3 positions are highly desirable for achieving high affinity binding to 
WDR5. These positions were further explored using a series of unnatural amino acids 
with small and constrained hydrophobic side chains. The tripeptides VRA and ARV were 
used as template for these modifications, since Val is favorable at both positions. The 
results are summarized in Tables 9 and 10. 
Similar binding affinities were observed when the Ala in ARV is replaced with 
either tert-Leu (Tle) (4g) or norvaline (Nva) (4h) (Table 9). Cyclopentylglycine (Cpg) 
(4i) at this position decreases the binding affinity by 15 times, whereas phenylglycine (4j) 
reduces the affinity by a factor of 50. Changing the chiral center in 4j, yielding 4k, 
further decreases the binding by >10-fold. Introduction of another methyl group in the Cα 
carbon (4e), however, improves the affinity by 10-fold and therefore a series of 
compounds using conformationally constrained cyclopropyl, cyclobutyl, cyclopentyl and 
cyclohexyl groups were synthesized. While 4a with a cyclopropyl group, is only 2 times 
less potent than ARV peptide, the other three compounds have improved binding 
affinities. Compound 4b with a cyclobutyl group, for example, is 10 times more potent 
than ARV and as potent as 4e. 
 
33 
 
Table 9: Binding affinities of Ac-XRV-NH2 analogs designed to further investigate S1 pocket. 
Compound R4 R5 IC50 ± SD (µM) Ki ± SD (µM) 
3c ARV -H 0.11± 0.02 0.020 ± 0.003 
4a ACPC-RV 0.26 ± 0.06 0.06 ± 0.01 
4b CycVal-RV 0.010 ± 0.008 0.002 ± 0.001 
4c CycLeu-RV 0.040 ± 0.003 0.009 ± 0.001 
4d homocycloLeu-RV 0.04 ± 0.01 0.007 ± 0.002 
4e α-MeAla-RV 0.010 ± 0.002 0.002 ± 0.0005 
4f Deg-RV 0.02 ± 0.01 0.004 ± 0.002 
4g Tle-RV -H 0.18 ± 0.04 0.040 ± 0.005 
4h Nva-RV -H 0.18 ± 0.01 0.040 ± 0.002 
4i Cpg-RV -H 1.56 ± 0.30 0.34 ± 0.06 
4j Phg-RV -H 5.4 ± 1.1 1.20 ± 0.25 
4k D-Phg-RV -H 68 ± 4 14.6 ± 0.80 
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Next, similar modifications at the Ala3 position in VRA peptide were performed 
giving the results shown in Table 10. Compound 5c with a constrained cyclopentyl side 
chain is 2 times more potent than VRA, while 5d with a cyclohexyl group is 2 times less 
potent than VRA. All the other modifications resulted in a decrease in binding affinity of 
at least an order of magnitude. 
Table 10: Binding affinities of Ac-VRX-NH2 analogs designed to further investigate S4 pocket. 
Compound R6 R7 IC50 ± SD (µM) Ki ± SD (µM) 
1c VRA -H  0.24 ± 0.03 0.050 ± 0.005 
5a VR-ACPC 2.71 ± 0.34 0.6 ± 0.1  
5b VR-CycVal 2.43 ± 0.55 0.52 ± 0.12 
5c VR-CycLeu 0.09 ± 0.01 0.018 ± 0.001 
5d VR-homocycloLeu 0.44 ± 0.15 0.44 ± 0.15 
5e VR-α-MeAla 
  
7.44 ± 0.15 1.6 ± 0.2 
5f VR-Tle -H 41 ± 7 8.7 ± 1.5 
5g VR-Cpg -H  41 ± 5 8.8 ± 1.1 
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Finally, the most favorable modifications identified at Ala1 and Ala3 positions 
were combined. For Ala1 position, those used in 4b, 4e and 4f and for the Ala3 position, 
those used in 3b, 3i and 5c were selected. These led to compounds 6a-6g (Table 11). 
Compounds 6a, 6c, 6d and 6f have IC50 values of 5-9 nM with Ki values of  1nM. In 
direct comparison, compounds 6a and 6d are 100 times more potent than the initial ARA 
tripeptide (Ki = 120 nM). 
Table 11: Binding affinities and effective permeability of the trimeric peptidomimetics combining favorable 
groups at Ala1 and Ala3 positions. 
Compound R4 R5 R6 R7 
IC50 ± SD 
(nM) 
Ki ± SD 
(nM) 
Pe 
(x10
-6
 cm
2
/s)
ARA  -H -H 540 ± 30 120 ± 10 < 0.01 
6a  -H 5 ± 1 < 1 < 0.01 
6b   36 ± 5 8 ± 2 < 0.01 
6c   -H 6 ± 1 < 1 NT* 
6d 
 
-H  5 ± 1 < 1 < 0.01 
6e 
 
32 ± 7 6 ± 2 NT* 
6f 
 
-H 9 ± 1 1.0 ± 0.3 < 0.01 
6g   80 ± 14 16 ± 3 < 0.01 
 *Not tested 
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4.3 Evaluation of Permeability of Peptides and Peptidomimetics 
 
Many peptides and peptidomimetics have low cell permeability. Therefore the 
permeability of ARA peptide and a number of potent peptidomimetics in Table 11 (6a, 
6b, 6e and 6g) was evaluated using a Parallel Artificial Membrane Permeability Assay 
(PAMPA), which measures the passive diffusion permeability in vitro. The data showed 
that peptidomimetics 6a, 6b, 6e and 6g and ARA peptide all have a permeability 
coefficient (Pe) value of < 0.01 (Table 11), suggesting that these compounds may have 
poor passive cell permeability. 
4.4 Further Modifications at the N- and C- terminus to Improve Cell Permeability 
 
The PAMPA data with potent peptidomimetics 6a, 6b, 6e and 6g show that these 
compounds are likely to have very poor passive cell permeability, which suggested that 
additional optimization to improve the permeability of the peptidomimetics is necessary. 
One of the commonly used methods to improve cell permeability is to increase 
hydrophobicity of the compounds. Therefore further modifications were performed at 
both the N- and C-terminals of ARA peptide with a goal of identifying additional 
modifications that would increase the overall hydrophobicity without detrimental effect 
on binding to WDR5. 
Based upon the predicted binding model of Ac-ARA-NH2 peptide with WDR5, 
N-terminal portion of the molecule is projected towards a small hydrophobic pocket (S5 
pocket, Figure 13a-b) formed by G89 and A65. Thus the methyl group of the acetyl 
group was modified with larger hydrophobic groups. As shown in Table 12, small groups 
such as isopropyl (7a, Ki = 0.04 μM) and cyclopropyl (7b, Ki = 0.11 μM) are much 
preferred over large (7g, Ki = > 65 μM) or branched (7f, Ki = 4.7 μM) groups. The most 
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favorable group at this position is isopropyl (7a, Ki = 0.04 μM), which improves the 
binding affinity by 3 times compared to methyl in Ac-ARA-NH2. 
Table 12: Binding affinities of the ARA peptides with N-terminal modifications. 
Compound R8 IC50 ± SD (µM) Ki ± SD (µM) 
ARA 0.54 ± 0.03  0.12 ± 0.01 
7a 0.17 ± 0.06 0.04 ± 0.01 
7b 0.5 ± 0.03 0.11 ± 0.01 
7c 5.1 ± 0.5 1.1 ± 0.1 
7d 0.7 ± 0.02 0.16 ± 0.01 
7e 23.4 ± 1.7 5.1 ± 0.4 
7f 22 ± 2 4.7 ± 0.5 
7g > 300 > 65 
7h > 100 > 5 
7i > 100 > 20 
7j 2.5 ± 0.4 0.54 ± 0.09  
7k 17.4 ± 0.3 3.74 ± 0.06 
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The C-terminal amide in Ac-ARA-NH2 is projected close to a small hydrophobic 
patch (the S3 pocket) formed by Y260 and K259 side chains (Figure 13a-b). Similar to 
the N-terminal modifications, this part of the molecule was substituted with different 
hydrophobic groups and the binding data are summarized in Table 13. All the 
modifications larger than methyl (8b-8g) improve the binding affinity. In particular, the 
biphenylmethyl group in 8g enhances the binding affinity by >10-fold. 
Table 13: Binding affinities of the ARA peptides with C-terminal amide modifications. 
 
Compound R9 IC50 ± SD (µM) Ki ± SD (µM) 
ARA      0.54 ± 0.03 0.12 ± 0.01  
8a (Δ2a)      0.70 ± 0.14 0.15 ± 0.03  
8b 
     0.16 ± 0.1 0.05 ± 0.01 
8c 
     0.10 ± 0.06 0.02 ± 0.01 
8d 
     0.28 ± 0.06 0.06 ± 0.01 
8e 
     0.34 ± 0.08 0.06 ± 0.02 
8f 
 
    0.12 ± 0.02 0.03 ± 0.004 
8g 
 
    0.04 ± 0.01 0.007 ± 0.002 
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4.5 Design of Potent and Cell Permeable Peptidomimetics (MM-101 and MM-102)  
 
The favorable groups for N- and C-terminals were combined with those of Ala1 
and Ala3 positions to produce a potent peptidomimetic with improved cellular 
permeability. For N- and C-terminal modifications isopropyl and biphenylmethyl groups 
were chosen, respectively, diethyl glycine (Deg) for Ala1 and cycloleucine (CycLeu) for 
Ala3 positions were preferred. Combination of all the modifications led to design of MM-
101 (MLL1 mimetic 101), which binds to WDR5 with an IC50 value of < 5 nM and a Ki 
value of < 1 nM. Moreover, fluoro (MM-102) and chloro (MM-103) analogs were 
designed, and found that both of the compounds have similar sub-nanomolar binding 
affinity to WDR5. On the other hand, due to low solubility profile of the chloro analog 
(MM-103), this compound was not studied further.     
 
Table 14: Structures and binding affinities of MM-101 and analogs. 
Compound R10 IC50 ± SD (nM) Ki (nM) Pe (x10
-6
 cm
2
/s) 
MM-101 -H 2.9 ± 1.4 < 1 0.52 ± 0.14  
MM-102 -F 2.4 ± 1.7 < 1 0.05  0.01 
MM-103 -Cl 4.5 ± 0.6 < 1 ND* 
 *Not determined 
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4.6 Determination of Crystal Structures of MM-101 and MM-102 in Complex 
with WDR5 
 
  To provide a structural basis for high affinity binding of MM-101 and MM-102 to 
WDR5 and for further structure-based optimization, crystal structures of these inhibitors 
complexed with WDR5 were determined at a resolution of 3.4 Å and 2.6 Å, respectively. 
As compared to the previously published apo-structure59, WDR5 adopts an almost 
identical configuration, with a RMSD value of 0.58 Å for 303 Cα atoms (Figure 14a). 
Consistent with the design strategy, MM-101 binds to the central channel of the WD40 
propeller where MLL1 peptides bind (Figure 14b). Similar to that observed in the WIN 
peptide two intramolecular hydrogen bonds are formed in MM-101 that stabilizes the 
molecule in a short 310-helix conformation (Figure 14c). Interaction network between 
MM-101 and WDR5 is also similar to that of MLL1 peptides. The Arg side chain of 
MM-101 penetrates deeply into the central channel of WDR5, and is sandwiched 
between the two aromatic rings of F133 and F263. The guanidinium group forms 
hydrogen bonds with the main chain carbonyls of C261, S175 and S91. Additionally, the 
N-terminal amide hydrogen bonds to D107, which has been shown to be a critical residue 
for binding to WDR5. Besides electrostatic interactions, MM-101 makes extensive 
hydrophobic packing against hydrophobic pockets surrounded by Y131, F149, F133, 
Y191, I305, Y260, K259, L88, L321, A47 and A65 from WDR5. 
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Figure 14: Crystal structure of WDR5-MM-101 complex. 
WDR5 in the complex is colored in green. Carbon atoms in MM-101 are shown in yellow, nitrogen and
oxygen atoms are colored in blue and red, respectively. (a) WDR5 in the complex shows the identical
configuration as apo WDR5 (PDB:2H14), colored in magenta. (b) The overall structure of WDR5-MM-
101 complex. The electron density (2Fo-Fc) map, contoured to 1δ is shown for MM-101. (c) The MM-
101 occupies the same pocket as MLL1 and exhibits a 310-helical configuration. The intermolecular
hydrogen bonds in compound A are shown in magenta dotted lines. (d) Stereo view of the interface
between MM-101 (yellow) and WDR5 (green). MM-101 and WDR5 pack across an extensive
interface, involving both hydrophobic packing and hydrogen bonds (shown in magenta dotted lines).  
42 
 
 
Figure 15: Crystal structure of WDR5-MM-102 complex.  
 
(a) The overall structure of WDR5-MM-102 complex. WDR5 is colored in green and MM-102 is colored
in yellow. The electron density (2Fo-Fc) map, contoured to 1δ is shown for MM-102. (b) MM-102
occupies the same pocket as MLL1 and also exhibits a 310-helical configuration. MLL1 and WDR5 from
WDR5-MLL1 complex (PDB: 3EG6) is shown in cyan and magenta respectively. (c) The comparison of
MM-101 and MM-102 in WDR5 complexes. In WDR5-MM-102 complex, WDR5 is colored in green
and MM-102 is colored in yellow. In WDR5-MM-101 complex, WDR5 is colored in salmon and MM-
101 is in cyan. (d) Stereo view of the interface between compound MM-102 (yellow) and WDR5
(green). MM-102 and WDR5 pack across an extensive interface, involving both hydrophobic packing
and hydrogen bonds (shown in magenta dotted lines). Water molecules are shown in orange spheres. 
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MM-102 occupies the arginine binding pocket in WDR5 in the same manner as 
MM-101 and the WIN peptide (Figure 15a). Both backbone and side chain orientations 
are also very similar to those in the WIN peptide (Figure 15b) and MM-101 (Figure 15c). 
A higher resolution (2.6 Å) structure of WDR5-MM-102 complex compared to that of 
WDR5-MM-101 (3.4 Å) reveals the detailed map of the interaction network (Figure 15d). 
All the nitrogen atoms in the molecule engage in either intra- or intermolecular hydrogen 
bonds. The N-terminal amide nitrogen and the Arg backbone nitrogen interact with D107 
and S91, respectively. The guanidino group hydrogen bonds with S91, F133, and C261 
directly and with S175 through a water molecule. The remaining amide nitrogen atoms at 
the C-terminal of Arg residue form intramolecular hydrogen bonds, similar to those in 
WIN peptide and MM-101. Two C-terminal main chain carbonyls in MM-102 take part 
in water-mediated hydrogen bonds with C261 and Y260, while the N-terminal carbonyls 
engage in intramolecular hydrogen bonds. The hydrophobic packing is similar to that of 
MM-101.  
4.7 Conclusion 
 
The initial modification study described in Chapter 3 revealed that -CO-ARA-
NH- in MLL1 is the minimal motif for high affinity binding to WDR5. In this part of the 
study, the MLL1 binding site in WDR5 was further probed with the goal of establishing 
an extensive structure activity relationship and obtaining highly potent peptides and 
peptidomimetics. Therefore modifications on Ala1, Arg2 and Ala3 were performed using 
both natural and unnatural amino acids. Modifications of Ala1 showed that small 
hydrophobic residues are preferred for high affinity binding to WDR5 and introduction of 
an additional methyl group into the Cα position enhances the binding affinity by >10 
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times. Of all the residues examined, unnatural amino acids with dimethyl, diethyl or a 
cyclobutyl group appear to be the best for enhancing the binding affinity. All the 
modifications on Arg2 residues led to complete loss of the binding affinity, indicating the 
essential role of this residue. For Ala3, as with Ala1, residues with small hydrophobic 
groups are also preferred for binding. Residues with an ethyl or a cyclopentyl side chain 
are the most preferred. 
Based upon these SAR data, a number of highly potent peptidomimetics have 
been designed. These include compounds 6a and 6d. Both compounds have IC50 values 
of 5 nM with estimated Ki values of < 1 nM. In direct comparison, 6a and 6d are 100 
times more potent than the initial Ac-ARA-NH2 peptide derived from MLL1. 
In the next step, efforts were focused on improvement of cellular permeability of 
these potent peptidomimetics. Both N- and C-terminal modifications with hydrophobic 
groups helped not only to improve the permeability but also to increase binding affinity. 
Therefore, MM-101 and MM-102 were designed by combining the most favorable 
groups for binding and cell permeability. Consistent with the design, MM-101 has an 
improved cell-permeability based upon the in vitro permeability assay.  
Finally, the crystal structures of both MM-101 and MM-102 complexed with 
WDR5 were determined, and showed that they indeed bind to WDR5 with a similar 
binding mode as MLL1 peptides. These co-crystal structures also provide the solid 
foundation for further structure based design to further optimize MM-101/MM-102 
toward developing a new class of anticancer therapy for the treatment of acute leukemia 
harboring MLL1 fusion protein. 
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CHAPTER 5  
Biochemical and Biological Evaluation MLL1-WDR5 Interaction Inhibitors 
In Chapter 4 the design of inhibitors (6a-6f, MM-101, MM-102, MM-103) with 
high binding affinities for WDR5 was described. It is critical to show that binding of 
these inhibitors to WDR5 can block the interaction between MLL1 and WDR5. 
Therefore, initially MM-101 and MM-102 were examined whether they inhibit MLL1-
WDR5 interaction using recombinant proteins and nuclear fractions of cell lysate, 
respectively. Next, whether inhibition of MLL1-WDR5 interaction could impair the 
catalytic activity of MLL1 core complex with MM-101 was addressed. Importantly, 
selected compounds were analyzed for their inhibition of HoxA9 and Meis-1 expression 
in MLL1-AF9 transduced murine bone marrow cells and for the inhibition of cell growth 
in cells with and without MLL1 fusion protein. In order to interpret the experimental 
results correctly it is essential to show if the selected inhibitors are soluble and stable in 
the assay conditions. Therefore, initially MM-101 was tested for its solubility and 
stability. 
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5.1 Solubility Analysis of MM-101 
 
Thermokinetic solubility of MM-101 in PBS (phosphate buffered saline, pH 7.4) 
and H2O was tested. PBS or H2O was added to serial dilutions of MM-101 in DMSO, and 
shook for 1.5-24 h at room temperature. Absorbance at 485 nm was measured for any 
precipitation. At 2 mM and lower concentrations the compound is soluble for both 
solvents. Next 4 mM, 2 mM and 1.5 mM solutions of MM-101 in H2O were prepared 
from powder form, in order to compare the thermokinetic and thermodynamic solubilities 
of the compound. MM-101 precipitates in both 4 mM and 2 mM H2O solutions, while 
completely dissolves in 1.5 mM solution of H2O. Therefore it was concluded that MM-
101 has 1.5 mM solubility in H2O and this is satisfactory for the experiments described 
below.    
5.2 Stability Analysis of MM-101 against Trypsin Degradation 
 
One of the main disadvantages of peptides for drug development is their 
susceptibility to proteolytic degradation, which causes their low bioavailability profile. 
Introducing unnatural amino acids would help to increase peptide stability since the 
proteases recognizes natural amino acids. To address this issue, MM-101 was tested for 
its trypsin stability at physiological pH. Trypsin is a serine protease and cleaves peptides 
from the C-terminus of lysine or arginine residues. Because MM-101 and the analogs 
described here contain an arginine residue it was important to assess the stability against 
trypsin degradation. The tested compound, tryptophan (internal standard) and trypsin 
were incubated in PBS at 37 °C. At the indicated time point a sample from this solution 
was withdrawn and mixed with equal volume of 20% trifluoroacetic acid to stop the 
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enzymatic activity of trypsin. This sample was then analyzed with analytical RP-HPLC 
for AUC using tryptophan as the internal control. Initially ARV (3c) peptide was tested 
as a control since this peptide would be cleaved by trypsin. 100% of ARV is cleaved in 
1h showing that trypsin is active under the assay conditions (Figure 16). Next MM-101 
was analyzed using the same conditions. Only 20% of MM-101 is cleaved in 24 h (1 day) 
and 50% of the compound is still stable after 4 days of incubation (Figure 16). This 
shows that combination of N- and C-terminal modifications with unnatural amino acids in 
the molecule improves the enzymatic stability significantly.  
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Figure 16:  Trypsin stability of MM-101 and ARV peptide.
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5.3 Stability Analysis of MM-101 in Cell Culture Media 
 
Before testing the inhibitors activity in cell lines, it was important to confirm their 
stability in culture media used for these cell lines. Therefore three different 
concentrations (100, 50, 10 µM) of MM-101 were incubated in RPMI-1640 media 
containing 10% fetal bovine serum (FBS) up to 12 days at 37 °C. Samples at the indicted 
time points were analyzed in analytical RP-HPLC. As shown in Figure 17, MM-101 is 
stable under the assay conditions. No significant decrease in the concentration of MM-
101 was observed during the experiment. 
 
 
 
 
 
0
500000
1000000
1.5100 6
2.0100 6
2.5100 6
100 M
  50 M
(AUC)
  10 M
0  2   4  6 8 10 12 0  2  4 6  8 10 12 0 2  4  6 8 10 12 days
Figure 17: Stability of MM-101 in RPMI-1640 Media measured by analytical RP-HPLC at
the indicated time points. 
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5.4 Inhibition of MLL1-WDR5 Interaction 
 
MM-101 was tested to inhibit MLL1C-WDR5 interaction using Biacore assay, 
which uses Surface Plasmon Resonance (SPR) to monitor the interaction between 
molecules. MLL1C was attached to the sensor chip and WDR5, pre-equilibrated with 
MM-101, was injected. 
MM-101 disrupts the interaction of MLL1C and WDR5 in this Biacore assay with 
an IC50 of 13 nM (Figure 18), which is in agreement with its binding affinity to WDR5 
(IC50 = 2.9 nM and Ki < 1) as measured with the competitive binding assay (Table 14). 
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R
U
Figure 18: Inhibition curve of MLL1C and WDR5
interaction with MM-101 using SPR experiment. 
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Next MM-102 activity to block MLL1C-WDR5 interaction in the nuclear fractions 
of cell lysates was analyzed. Flag-WDR5 transduced HEK-293T cells were lysed and 
fractionated. Nuclear fractions were treated with increasing concentrations of MM-102 
and immunoprecipitated with Flag-antibody followed by blotting individually with 
MLL1C, WDR5 or RbBP5 antibodies. As shown in Figure 19, increasing concentrations 
(i.e. 0.2, 2 and 20 µM) of MM-102 disrupts the interaction of WDR5 with MLL1C in 
vitro. However, interaction of WDR5 with RbBP5 is not effected by MM-102, proving 
that the designed inhibitors are specifically targeting the top binding pocket in WDR5, 
which is used for MLL1 interaction.  
5.5 Inhibition of H3K4 Methyltransferase Activity of the MLL1 Core Complex 
 
Since the interaction of WDR5 and MLL1 is critical for H3K4 methyltransferase 
activity of the MLL1 complex, it was predicted that small-molecule inhibitors designed 
to block this interaction could effectively inhibit the catalytic activity. 
α-MLL-C
α-RbBP5
α-WDR5
Flag-WDR5 IP
MM-102
0.2μM    2.0μM     20μM
2%
Input
Figure 19: Inhibition of MLL1C-WDR5 interaction in HEK-293T nuclear fractions. 
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To directly test this hypothesis, a fully reconstituted in vitro functional assay was 
developed using recombinant MLL1C, WDR5, RbBP5 and ASH2L proteins to form the 
core complex, an H3-10mer peptide as the substrate, and radio-labeled 3H-S-adenosyl 
methionine as the methyl donor. H3K4 methyltransferase activity is monitored by 
incorporation of the radioactivity (3H-labeled methyl) into Lys4 residue of H3 peptide 
determined with a scintillation counter. Using this assay, initially the inhibitory activity 
for a number of compounds with different ranges of binding affinities to WDR5 as 
determined in the FP-based assay were evaluated. The results are shown in Figure 20. 
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Figure 20: Comparison of activities of selected compounds in HMTase and competitive binding assays. (a)
Inhibition of HMTase activity of reconstituted MLL1 core complex as measured with scintillation counter assay
in the presence of selected inhibitors. (b) Competitive binding curves of the same inhibitors for WDR5. 
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Compounds 6a and 6c, which have the highest binding affinities to WDR5 (IC50 = 
5 nM and Ki < 1 nM for both compounds), also show the most potent inhibitory activity 
in the functional assay with IC50 values of 0.5 µM and 0.9 µM, respectively.  Compound 
3b (ARAbu), which binds to WDR5 with an IC50 = 30 nM (Ki = 6 nM), has an IC50 value 
of 1.8 µM to inhibit H3K4 methyltransferase activity of the core complex and is thus 2-3 
times less potent than 6a and 6c. VRA, which binds to WDR5 with an IC50 value of 0.24 
µM (Ki = 0.05 µM), has an IC50 = 12.1 µM in the functional assay. Finally, GRA, which 
has an IC50 value of 77.4 µM to WDR5 (Ki = 16.7 µM) in the binding assay, fails to 
inhibit the HMTase activity at concentrations as high as 100 µM. Therefore, this data 
show that peptides or peptidomimetics with high-affinity for WDR5 can effectively 
inhibit the H3K4 methyltransferase activity of the reconstituted MLL1 core complex in 
the in vitro functional assay. The rank-order of the inhibitory activity of these compounds 
in the functional assay is in an excellent agreement with that of their affinities to WDR5, 
as compared in Figure 20a and Figure 20b. Of note, the apparent discrepancy between the 
IC50 values in the binding and HMTase assays for each compound is due to the fact that 
125-fold higher WRD5 protein (500 nM) was used in the functional assay than that (4 
nM) in the binding assay.  
MM-101 and MM-102 were also tested in this functional assay, and inhibited the 
HMTase activity of the core complex with IC50 = 5 nM and 3 nM, respectively.  
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5.6 Inhibition of MLL1 Target Gene Expression 
 
The ability of MM-102 to inhibit expression of HoxA9 and Meis-1, two key genes 
regulated by MLL1 activity, was investigated. MLL1-AF9 transduced murine bone 
marrow cells were treated with MM-102 for 7 days, followed by gene expression analysis 
with qRT-PCR. Results are shown in Figure 21. HoxA9 expression decreases with MM-
102 treatment in a dose dependent manner. Approximately 40% and 60% reduction in 
gene expression was observed with 25 and 50 µM, respectively, when compared with the 
non-treated (NT) control. A decrease in HoxA9 expression with DMSO treatment was 
observed in the experiment shown in Figure 21a. This observation is due to high error bar 
and was not observed in an independent experiment. Meis-1 expression decreases 
moderately with the highest concentration (50 µM) of MM-102 treatment (Figure 21b).  
 
Figure 21: qRT-PCR analysis of MLL1-AF9 transduced cells upon MM-102 treatment. 
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a) b)
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MM-101 was also tested in the same assay. However, no significant inhibition of 
gene expression was observed, which might be due to lower permeability profile of the 
compound and therefore not selected for further studies.    
These data show that MM-102 can reduce expression levels of two critical MLL1 
target genes required for leukemogenesis, strongly supporting the hypothesis that 
inhibition of MLL1-WDR5 interaction can be used to regulate expression levels of MLL1 
target genes.  
5.7 Inhibition of Cell Growth 
 
HoxA9 expression is essential for the self-renewal of both hematopoietic stem 
cells and leukemia cells. shRNA knockdown of HoxA9 in a panel of acute leukemia cell 
lines with and without MLL1 fusion proteins has been shown to differentially inhibit 
growth of cells with MLL1 translocation.66 Therefore, it was predicted that growth of cell 
lines with chimeric MLL1 proteins would be inhibited with MM-102. Leukemia cell lines 
with MLL1 fusion proteins, MV4:11 and KOPN8, or without MLL1 fusion proteins, 
K562, were treated with MM-102 for 2, 4 or 7 days. Cell growth inhibition was analyzed 
with CellTiter-Glo® Luminescent Cell Viability Assay. As shown in Figure 22, MM-102 
Figure 22: Growth inhibition of selected leukemia cell lines with MM-102 normalized to DMSO control.
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differentially inhibits growth of MV4:11 and KOPN8 cells in time and dose dependent 
manners when compared to that of K562 cells. These findings suggest that the selective 
inhibition of cell growth with MM-102 is through targeting function of MLL1 activity. 
5.8 Conclusion 
 
This part of the study is aimed to investigate whether the inhibitors that can block 
MLL1-WDR5 interaction can successfully downregulate expression of crucial MLL1 
target genes, HoxA9 and Meis-1, and selectively inhibit self-renewal of leukemia cell 
lines with MLL1 fusion proteins. MM-101 and MM-102 was selected for these studies. 
Before testing the inhibitors in cellular and cell free assays, it was necessary to show if 
they are soluble and stable under the assay conditions. Therefore, MM-101 was tested for 
thermodynamic and thermokinetic solubility and found to have over 1 mM solubility, 
which is sufficient for the studies described here. Significant improvement with MM-101 
against trypsin stability was observed when compared to ARV peptide showing the 
success of peptidomimetic design in this study.  
Next, the hypothesis to inhibit MLL1 fusion protein activity in leukemia through 
blocking the wild-type MLL1 activity and inhibiting MLL1-WDR5 interaction was 
tested. Initially, inhibition of protein-protein interaction in in vitro systems was 
investigated. MM-101 can block recombinant MLL1C-WDR5 interaction with an IC50 of 
13 nM and MM-102 prevents MLL1C binding to WDR5 in nuclear fractions of HEK-
293T. Moreover, association of WDR5 with RbBP5 is not effected by MM-102, showing 
the specific binding of the designed compounds to MLL1 binding pocket, consistent with 
the crystal structure analysis.   
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 To determine if compounds that bind to WDR5 protein with high affinities in the 
FP-based competitive binding assays will effectively inhibit the H3K4 methyltransferase 
activity of MLL1, a fully reconstituted in vitro functional assay have been developed and 
optimized using recombinant MLL1, WDR5, RbBP5 and ASH2L proteins, a H3 peptide, 
and a radio-labeled co-factor 3H-S-adenosyl methionine. Using this functional assay, the 
inhibitory activities of several peptides and peptidomimetics with a large range of binding 
affinities to WRD5 were evaluated. These experiments showed that peptides and 
peptidomimetics with high binding affinities to WDR5 can indeed effectively inhibit the 
MLL1 H3K4 methyltransferase activity in this fully reconstituted functional assay, while 
compounds with lower binding affinities show less potent activity. Furthermore, their 
rank-order in inhibition of the MLL1 methyltransferase activity in the functional assay 
for these compounds is in a good agreement with that obtained from the WDR5 binding 
assay. 
 Analysis of HoxA9 and Meis-1 expression in MLL1-AF9 transduced murine bone 
marrow cells treated with MM-102 revealed that expression of HoxA9 can be reduced 
with the inhibitor significantly (60%), while a moderate decrease is observed for Meis-1 
expression (20%). These data show that MM-102 can reduce expression levels of two 
critical MLL1 target genes required for leukemogenesis, strongly supporting the 
hypothesis that inhibition of MLL1-WDR5 interaction can be used to regulate expression 
levels of MLL1 target genes. However, lack of effect with MM-101 in the same 
conditions suggests that MM-101 has lower cellular permeability compared to MM-102. 
The specificity of MM-102 to inhibit cell growth in AML and ALL cell lines with 
and without MLL1 translocation was evaluated. MV4:11 and KOPN8 cell lines, with 
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MLL1-AF4 and MLL1-ENL fusion proteins respectively, are more sensitive to MM-102 
when compared with K562 cell line without MLL1 abnormality and the differential effect 
appears after 4 day treatment.   
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CHAPTER 6  
Summary and Future Directions 
6.1 Rationale and Design of the Study  
 
Acute leukemia is a disease of the hematopoietic system characterized by 
abnormal proliferation of immature white blood cells (leukocytes) which do not execute 
their normal function. MLL1, a protein associated with leukemogenesis, is one of the 
most frequently misregulated proteins in acute leukemia. Translocations of the 
chromosome 11q23 lead to highly leukemogenic chimeric MLL1 proteins, which exert 
their function through upregulation of HoxA9 and Meis-1 genes.9,10 The HoxA9 protein 
induces self-renewal of leukemic stem cells, and Meis-1 is a co-factor for HoxA9 
function.4,5 Recent research has shown the significance of co-expression of wild type 
MLL1 with MLL1 fusion protein in leukemogenesis53 and accordingly, the research 
described here had the aim of suppressing the MLL1 function in leukemia by targeting 
the catalytic activity of wild type MLL1 (Figure 23). Our hypothesis was that blocking 
MLL1-WDR5 interaction could inhibit H3K4 methyltransferase activity of MLL1, 
resulting in decrease in target gene expression. Downregulation of HoxA9 and Meis-1 
would suppress self-renewal and induce differentiation of the leukemia cells, which 
eventually inhibit transforming capacity of the leukemia cells. 
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Figure 23: The strategy and rationale to inhibit the function of the MLL1 fusion protein in leukemogenesis. 
 
 To design potent MLL1 mimetics, inhibitors of MLL1-WDR5 interaction, the 
12mer WIN peptide was used as a starting point. The minimal structure required for 
interaction with the top binding site of WDR5 was investigated and the tripeptide motif -
CO-ARA-NH- was identified as the minimal motif necessary for high affinity binding to 
WDR5. A modification study was performed using Ac-ARA-NH2, a peptide that contains 
this minimal motif. Modifications at the arginine site invariably resulted in complete loss 
of binding, and were therefore not pursued.  Both alanine residues were replaced with 
polar and hydrophobic amino acids of increasing size and it was found that small 
hydrophobic amino acids at these positions are preferred for ligand binding to WDR5 and 
unnatural amino acids with constrained side chains at the Ala1 and Ala3 positions were 
also analyzed. Combination of the most favorable groups led to the design of 
peptidomimetics which have sub-nanomolar Ki for WDR5 and block the catalytic activity 
of MLL1 core complex in a functional assay. Efforts to improve the permeability and 
cellular function of the inhibitors by substituting N- and C-terminal of the 
peptidomimetics with hydrophobic groups led to the design of two lead compounds, 
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MM-101 and MM-102. Crystal structure information confirmed that the compounds bind 
to the top binding pocket in WDR5 and provided information for the structure based 
design of further generations of inhibitors. Both MM-101 and MM-102 inhibit the 
interaction of MLL1C with WDR5 and the catalytic activity of the core complex in vitro. 
Two subsequent questions were addressed; can inhibition of MLL1-WDR5 interaction 
suppress HoxA9 and Meis-1 expression and is it capable of inhibiting self-renewal of the 
leukemia cells? It was successfully shown that MM-102 decreases expression of both 
HoxA9 and Meis-1 in MLL1-AF9 transduced bone marrow cells and differentially inhibits 
growth of cells with MLL1 fusion protein. 
6.2 Significance of the Study 
 
This research validates a new target in leukemia therapy; compounds with high 
binding affinities for WDR5 can block the MLL1 binding to WDR5 and can inhibit the 
catalytic activity of MLL1 core complex leading to reduction in target gene expression 
and inhibition of growth of cells expressing MLL1 fusion proteins. These findings 
strongly suggest that small-molecule inhibitors of WDR5-MLL1 interaction can block the 
misregulated cellular function of MLL1. Therefore, targeting MLL1-WDR5 interaction 
has the potential to develop a new class of therapy for the treatment of leukemia and 
other types of cancer, in which MLL1 activity plays a role.  
This study showed for the first time, that a potent inhibitor of the MLL1-WDR5 
interaction can reduce the expression of HoxA9 and Meis-1, and can selectively inhibit 
growth of cells with MLL1 fusion proteins. These findings support the earlier studies 
suggesting the essential role of wild type MLL1 in the function of MLL1 fusion 
proteins.52,53  
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SAR studies and crystal structure information of inhibitor-WDR5 complexes 
revealed a detailed map of ligand-WDR5 interaction. Therefore this study can be the 
basis for the development of non-peptidic small molecule inhibitors of MLL1-WDR5 
interaction.    
6.3 Future Directions 
Improving Cellular Permeability of the MLL1 Mimetics 
In an FP-based competitive binding assay, both MM-101 and MM-102 have sub-
nanomolar affinities for WDR5, and the latter inhibits MLL1C-WDR5 interaction with Ki 
= 13 nM. However, 25-50 µM of MM-102 is required to inhibit HoxA9 expression and no 
inhibition was observed with MM-101 at the same concentrations. These observations 
suggest that those designed MLL1 mimetics may suffer from low cellular permeability, a 
common problem of peptide-based inhibitors stemming from the amide bonds they 
contain. Peptides make extensive hydrogen bonding with the surrounding water through 
their amide bonds resulting in high energy cost for desolvation during membrane 
transport. Cyclization constrains such molecules and promotes intramolecular hydrogen 
bond formation, which would decrease the interaction with the surrounding water. 
Moreover, the number and the polarity of amide bonds can be decreased to improve 
permeability. Methylation of the backbone nitrogen atoms has been shown to contribute 
to the permeability and it is also possible to replace the amide bond with isosteres. In 
addition to their contribution to permeability these proposed modifications would be 
expected to enhance the resistance to metabolism of MLL1-mimetics.       
 Non-peptidic small molecules are less susceptible to permeability and metabolism 
problems. As shown in Chapter 4, high affinity binding to WDR5 requires extensive 
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interaction with the protein and these interactions must be considered when designing 
small molecule non-peptidic inhibitors.  
Further Studies to Support the Target Validation 
 H3K4 methylation of target genes: Although MM-102 was shown to inhibit 
HoxA9 expression, it is necessary to show that this effect is due to specifically 
inhibition of H3K4 methyltransferase activity of the wild type MLL1 in cells. The 
CHIP assay could be used to detect the change in H3K4Me3 levels of HoxA9 loci 
in response to MM-102 treatment.    
 Differentiation: HoxA9 prevents differentiation and induces self-renewal in 
leukemic cells. Therefore, whether the decrease in HoxA9 level with MLL1 
mimetics could lead to cell differentiation can be addressed. 
 Testing MLL1-Mimetics in animal models: A next step would be testing cell 
permeable and metabolically stable potent MLL1 mimetics in animal leukemia 
models both to prevent onset of the disease and to develop a treatment for the 
disease. 
 Effects of MLL1-Mimetics on the other targets: Although the critical role of 
WDR5 in MLL1 complex is well established, its role in other H3K4 
methyltransferases has not been studied in detail. Similar to MLL1, the MLL2-4 
and hSet1a/b enzymes form a complex with WDR5, RbBP5 and ASH2L and it is 
essential to address the effect of MLL1 mimetics on the activity of these enzymes. 
WDR5 has been shown to be involved in the larger MLL1-MOF protein complex. 
MOF acetylates H4K16, which is a histone modification critical for HoxA9 
expression, and MLL1 has been shown to be essential for this activity. MLL1 
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mimetics could be used to investigate the role of WDR5 and/or the MLL1-WDR5 
interaction in the MLL1-MOF complex. 
Alternative Targets to Suppress MLL1 Activity in Leukemia  
The catalytic activity of wild-type MLL1 can be also targeted through RbBP5 or 
ASH2L both of which are necessary for the activity. The interaction surfaces between 
WDR5 and RbBP5, RbBP5 and ASH2L, MLL1 and RbBP5 are all potential sites for the 
inhibitor design. Alternatively, catalytic activity of MLL1 could be blocked through 
inhibiting the H3 substrate or S-adenosyl methionine (SAM) binding to the SET domain. 
Mimetics of substrate or cofactor could be designed based on the crystal structure of 
MLL1 SET domain in complex with H3 peptide and S-adenosyl homocysteine (SAH).67 
However, mimetics of SAM would lack in specificity since all the other 
methyltransferases use the same cofactor. In order to achieve specificity, compounds 
containing both the substrate and cofactor moieties could be designed based on the 
crystal structure information of MLL1 SET domain. 
Another approach for targeting wild type MLL1 activity could be inhibition of the 
proteolytic cleavage of MLL1 by Taspase 1 whose crystal structure is known.68 However, 
there are other substrates for Taspase 1 and thus, blocking MLL1 cleavage by Taspase 1 
will probably be an approach lacking in specificity.  
Alternatively, MLL1 fusion protein activity could be targeted. It has been shown 
that several MLL1 fusion proteins associate with Dot1L, the only known H3K79 
methyltransferase, and recruit Dot1L to up-regulate HoxA9 expression. Successful 
inhibition of MLL1 fusion protein activity in model cells and cell lines with a Dot1L 
inhibitor has already been demonstrated.69 
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Targeting both the wild-type and fusion proteins of MLL1 through their 
interaction with Menin could be another approach. Menin is a critical binding partner of 
MLL1N and is essential for HoxA9 expression.70 Menin interacts with N-terminus of 
MLL1 and this interaction is preserved within the fusion proteins.30,71 Therefore, dual 
targeting of MLL1 could be achieved and this would lead to a robust inhibition compared 
to the inhibition achieved by targeting only wild type or fusion protein activity.  
Inhibition of the interaction of HoxA9 with DNA is another approach. HoxA9 
uses a hexapeptide to interact with the minor groove and this hexapeptide might be 
starting point of another class of inhibitors.72 
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Appendix A 
Experimental 
1) Solid Phase Synthesis of the Peptides 
Peptides were synthesized manually or with an ABI 433 peptide synthesizer using 
Fmoc chemistry. Rink amide resin was used as the solid support. To avoid side reactions, 
amino acid residues were protected as follows: Glu (OtBu), His (Trt), Lys (Boc or Mtt), 
Gln (Trt), Arg (Pbf), Ser (OtBu), Thr (OtBu). HOBt/HBTU or DIC/HOAt was used as 
the coupling reagent. HCOOH/DIC/HOAt in DMF was used for on-bead formylation 
where the reaction was carried out in a flask rotated overnight at room temperature using 
rotavapor without applying vacuum. All the peptides were cleaved from the resin using a 
TFA:DTT:TIS:H2O (17.5ml:0.5g:0.5ml:1ml) cleavage cocktail which also led to removal 
of the protecting groups. The cleavage solution was evaporated and the crude product 
was precipitated with diethyl ether followed by HPLC purification using a C18 reversed 
phase column (Waters, Sunfire Prep C18, 19 mm × 150 mm, 5 μm). All the purified final 
peptides were analyzed by analytical RP-HPLC (Waters, Sunfire C18, 4.6 mm × 150 
mm, 5 μm) for purity, and the characterization of the peptides was determined by 
electrospray ionization mass spectroscopy (ESI-MS).  
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2) Synthesis of C-terminally Modified Compounds (2a-b, 8a-g) 
Ac-Ala-Arg(Pbf)-Ala-COOH peptide was synthesized using Fmoc-solid phase 
chemistry and 2-chlorotrityl chloride resin as the solid support (Scheme 1).  Fmoc-Ala-
OH (3 eq.) was loaded overnight in dichloromethane and in the presence of 3 eq. DIEA. 
Then, methanol was added to this mixture to and shaked for 30 min to endcap unreacted 
2-chlorotrityl group. Next, classical chain elongation was carried out with Fmoc 
chemistry. The carboxylic acid intermediate was cleaved from the resin by treatment with 
4 ml of 1% trifluoroacetic acid in dichloromethane (3×10 min).  The filtrate was 
evaporated and purified over the HPLC using the C18 reverse phase column. The Ac-
 
Scheme 1: Synthesis of C-terminally modified peptides. 
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AR(Pbf)A-COOH (0.2 mmol) was dissolved in 10 ml of THF, and 3 eq. HATU, 3 eq. 
HOAt, 5 eq. DIEA, and 3 eq. of the corresponding amine was added. The reaction 
mixture was stirred at room temperature for 24h, the solvent was evaporated and the 
crude product was purified by RP-HPLC.  The Pbf protected group from the arginine was 
removed by treatment with the cleavage cocktail TFA:DTT:TIS:H2O 
(17.5ml:0.5g:0.5ml:1ml), followed by HPLC purification (Waters, Sunfire™ Prep C18, 
19×150 mm, 5 µm).  
3) Synthesis of Δ2c 
The Ac-AR(Pbf)A-COOH intermediate (0.2 mmol) was dissolved in absolute 
methanol, and 0.5 ml of trifluoroacetic acid was added. The reaction mixture was stirred 
at room temperature for three days, the solvent was evaporated, and the Pbf protecting 
group was removed by treatment with the cleavage cocktail to give the final product 
which was purified by RP-HPLC (Waters, Sunfire™ Prep C18, 19×150 mm, 5 µm). 
 
 
 
Scheme 2: Synthesis of Δ2c
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4) Synthesis of the Tracers 
 
Scheme 3: Synthesis of the tracers 
The peptide was synthesized as described above with an Mtt protecting group on 
the C-terminal lysine residue. The fluorescein label, 5-FAM, was introduced to the side 
chain of C-terminal lysine group by removal of the Mtt protecting group with 5 ml of 1% 
trifluoroacetic acid in dichloromethane (4 × 10 min) followed by overnight treatment 
with 1.5 eq. of 5-carboxy fluorescein succinimide ester (5-FAM, SE) and 4 eq. of DIEA. 
The peptide was cleaved from the resin and purified over HPLC as described above. 
5) Binding Assay 
All the FP-based experiments were performed in Microfluor 2 Black, “U” 
Bottom, 96-well microtiter plates (Thermo Scientific) and FP was measured as mP units 
in a microplate reader (Tecan Ultra) with excitation at 485 nm and emission at 530 nm. 
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The Kd of the tracers and the IC50 value of the inhibitors were calculated using GraphPad 
Prism 4 software. 
a) Protein Expression and Purification for the Binding Assay (by Elizabeth C. 
Townsend) 
 
N-terminal His-tagged WDR5Δ23 (residues 24-334) was cloned into pET28A-
MHL vector by ligation independent cloning. This construct was gifted by A. 
Ruthenburg.65 It was expressed in Rosetta2-(DE3) pLysS cells (Novagen). Cells were 
grown to OD600=0.4-0.6 in 4 L of 2XTY at 30 oC, induced with 0.1mM IPTG at 16 oC for 
16h and harvested in 20 mM HEPES pH 7.5, 500 mM KCl, 10%  glycerol, 0.1 mg/ml 
PMSF, and 0.05% NP40. Cells were lysed by addition of 0.2 mg/ml hen egg white 
lysozyme followed by sonication and clarification (by centrifuging for 30 min at 15000 
rpm). The resin was washed 3 times for 10 min with 40 ml of lysis buffer. His-
WDR5Δ23 was eluted from the resin by 315 min elutions with 20 mM HEPES pH 7.5, 
100 mM KCl, 10% glycerol, 250 mM imidazole, pH 7.5. Eluates were clarified by 
centrifugation at 2000 rpm for 1 min, syringe-filtered through a 0.45 μM membrane 
(Millipore), and then loaded onto two 5 ml SP-Sepharose Hi-Trap columns using the 
AKTA purifier (GE Healthcare). Fractions were eluted in 20 mM HEPES pH 7.5, 10% 
glycerol with a KCl gradient from 0 to 1000 mM, and peak fractions were pooled and 
concentrated to 64 μM using an Amicon Ultra centrifugal filter, 10000 MWCO 
(Amicon). Concentrated protein was aliquoted and samples were frozen on dry ice and 
stored at -80 oC.  
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b) Saturation Binding Experiment to Determine Dissociation Constant (Kd) of 
the Tracers 
To dilutions of WDR5Δ23 (2.2-0 μM) in 100 μl of assay buffer (0.1 M phosphate, 
25 mM KCl, 0.01% Triton, pH 6.5), 20 μl of a fixed concentration of the tracer in the 
assay buffer was added, followed by an addition of 5 μl of DMSO to give 125 μl of total 
volume. Each assay had two controls: blank (without protein and tracer) and tracer only 
(without protein). The plates were incubated on a shaker at room temperature to reach 
equilibrium, and mP values were measured at the 3 h time point. 
c) Competitive Binding Experiments 
A preincubated complex solution of WDR5Δ23 and the tracer in 120 μl of assay 
buffer were added to dilutions of the test compound in 5 μl of DMSO, giving final 
concentrations of WDR5Δ23 and the tracer of 4 and 0.6 nM, respectively. Three control 
wells were included in each plate: blank (without protein and tracer), 100% inhibition 
(tracer only), and 0% inhibition (complex solution only). The plates were incubated with 
shaking at room temperature. The mP values were measured after five hours of 
incubation, and Ki values were calculated using the equation described previously.62 
6) Molecular Dynamics (MD) Simulation (by Denzil Bernard, Ph.D.) 
The crystal structure of WDR5 in complex with the WIN peptide (PDB: 3EG6) 
was used to construct the models of the peptides using Sybyl (Tripos, Inc.) with 
minimization of any mutation introduced. MD simulations were performed with Amber 
for 3 ns using explicit TIP3P solvent. After initial minimization of the solvent, the system 
was further relaxed with constraints on the backbone before final minimization. MD 
simulations involved a gradual increase in temperature to 300 K over 30 ps, while 
holding the solute constrained, followed by another 30 ps of simulation with the 
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constraint only on the backbone. Further equilibration was performed for 40 ps before the 
production run. SHAKE was applied to all bonds involving hydrogen atoms to permit a 
time step of 0.002 ps. Structures were saved every 1 ps for analysis. 
7) Parallel Artificial Membrane Permeability Assay (PAMPA) (by Liu Liu, Ph.D.) 
1% Lecithin solution (w/v) in dodecane was prepared and sonicated for 1 min 
with Fisher/Branson 500 probe sonicator to ensure complete dissolution. 5 μl of the 
lecithin/dodecane solution was carefully loaded on the PVDF (polyvinylidene fluoride) 
filter membrane of each acceptor plate well immediately followed by adding 150 μl of 
PBS (pH = 7.4) to each well of the acceptor plate. 300 μl of compound solution in PBS 
was loaded to the PTFE (polytetrafluoroethylene) donor plate in which controls were 
loaded as well to verify membrane integrity. The complete donor-acceptor assembly was 
incubated at room temperature for 16h in sealed container with humidity controlled. After 
incubation, concentrations of compounds and controls in both the donor and acceptor 
plates were determined by UV/Vis absorption spectrometry. Pe was calculated using the 
equation below; 
 
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VD = Volume of donor compartment 
VD = Volume of acceptor compartment 
Area = Active surface area of membrane 
Time = Incubation time 
[drug]acceptor = Conc. of compound in the acceptor compartment after incubation 
[drug]equilibrium = Conc. of compound at theoretical equilibrium (the resulting 
concentration if the donor and acceptor solution were simply mixed) 
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8) Determination of Crystal Structure of MM-101 and MM-102 in Complex with 
WDR5 (by Yong Chen, Ph.D.) 
a) Protein Preparation 
WDR5 (Δ23aa, NP_060058.1) was cloned into a pET28b-based vector with a 
6xHis-SUMO tag fused at the N-terminus. E. coli BL21(DE3) cells bearing expression 
plasmids were induced for 16h with 0.1 mM IPTG at 25 oC. The protein was purified by 
Ni-NTA affinity resin and on-bead digestion using Ulp1 protease, followed by the gel 
filtration chromatography on HiloadSuperdex 75 equilibrated with 25 mM Tris-HCl pH 
8.0 and 150 mM NaCl. The purified protein was concentrated to 30 mg per ml and stored 
at -80 oC for crystallization.  
b) Crystallization and Structural Determination 
WDR5-MM-101 binary complex was obtained by mixing WDR5 and MM-101 at 
molar ratio 1: 3 right before crystallization. The complex was crystallized at 25% PEG 
4000, 0.1M sodium acetate, pH 4.6, 0.2M ammonium sulfate. The crystals were 
harvested in the same buffer with 20% glycerol. The 3.4 Å data set was collected at 
Advanced Photon Source beamline 21ID-F and was processed by HKL2000.73 The 
crystal belongs to P1 space group. The structure was solved by molecular replacement by 
Phaser74 using the previously published WDR5 structure (2H14). Iterative cycles of 
refinement and modeling were carried out using Phenix and Coot.75,76 
WDR5-MM-102 binary complex was obtained by mixing WDR5 and MM-102 at 
molar ratio 1: 3 before crystallization. The complex was crystallized at 30% PEG8000, 
0.2M ammonium sulfate. The crystals were harvested in the same buffer with 20% 
glycerol. The 2.6 Å dataset was collected at Advanced Photon Source beamline 21ID-D 
and was processed by HKL2000. The crystal belongs to P21 space group. The structure 
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was solved by molecular replacement by Phaser using the previously published WDR5 
structure (2H14). There are four WDR5 molecules in one asymmetric unit. Iterative 
cycles of refinement and modeling were carried out using Phenix and Coot. 
Table 15: Data collection and refinement statistics for WDR5-MM-101 and WDR5-MM-102 complexes by 
molecular replacement. 
 WDR5-MM-101 WDR5-MM-102 
Data collection   
Space group P1 P21 
Cell dimensions   
a, b, c (Å) 48.943,105.985, 20.907 48.861,106.478,120.719 
, ,  () 90.002, 89.758, 90.034 90, 90.352, 90 
Wavelength(Å) 0.9785 0.9785  
Resolution (Å) 100-3.40 100-2.60 
Rmerge 0.08 (0.129)* 0.134 (0.399)* 
I / I 8.0(4.5) 8.0(4.5) 
Completeness (%) 90.5(68.9) 93.8(94.2) 
Redundancy 1.9(1.8) 2.7(2.3) 
Refinement   
Resolution (Å) 48-3.40 48.8-2.6 
No. reflections 30243 32146 
Rwork / Rfree 19.5/22.6 19.3/24.9 
No.  Atoms   
Protein 18856 9309 
Ligand(165b) 
Water 
368 192 
304 
B-factors   
Protein 61.1 26.2 
Ligand  52.3 25.9 
Water  23.9 
r.m.s deviations   
    Bond lengths (Å) 0.018 0.008 
    Bond angles () 1.912 1.200 
*Values in parentheses are for highest-resolution shell. 
9) Solubility Analysis of MM-101 
PBS (phosphate buffered saline, pH 7.4) or H2O was added to serial dilutions of 
MM-101 in DMSO and shook for 1.5-24 h at room temperature in 98-well cell culture 
plates. Absorbance at 485 nm was measured for any precipitation. 
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10) Stability Analysis of MM-101 
a) Stability Analysis of MM-101 against Trypsin Degradation  
Tested compound (200 µM), tryptophan (200 µM) and trypsin (10 nM) were incubated 
in PBS at 37 °C. At the indicated time point 100 µl from this solution was withdrawn and mixed 
with equal volume of 20% trifluoroacetic acid solution. The sample was analyzed with 
analytical RP-HPLC for AUC (area under curve) using tryptophan as internal control. 
b) Stability Analysis of MM-101 in Cell Culture Media 
100, 50 and 10 µM solutions of MM-101 were prepared in RPMI-1640 media. The 
solutions were incubated in a 6-well tissue culture plate for up to 12 days at 37 °C under 5% CO2. 
At the certain time point 200 µl of the solution was withdrawn and centrifuged at 13,000 rpm for 
5 min at 4 °C to remove serum proteins. The supernatant was collected and analyzed using 
analytical RP-HPLC for AUC.  
11) Inhibition of MLL1-WDR5 Interaction (by Elizabeth C. Townsend) 
a) Biacore Assay 
Purified MLL13762 was immobilized on the CM5 chip (GE Healthcare) using 
standard amide coupling chemistry. To monitor binding, purified WDR5 was diluted in 
HBS buffer, 10 mM HEPES pH 7.4, 150 mM NaCl, P20 0.005%, at concentrations 
ranging from 16 nM to 1000 nM.  WDR5 dilutions were injected at a flow rate of 60 μl 
for 120s and allowed to dissociate for 480s. Binding data was fit to the Drifting Fit 
baseline model using the Bioanalysis software. For inhibition, WDR5 at 60nM was 
combined with varying concentrations of MM-101, ranging from 0.9 to 240 nM.  
Dilutions of WDR5 plus inhibitor were injected over the MLL1 chip as in the binding 
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experiments.  Binding was monitored at 110s and plotted against inhibitor concentration 
using GraphPad Prism 5.0 and fit to determine the IC50. 
b) FLAG-Immunorprecipitation 
HEK-293T cells, stably transfected with a FLAG-WDR5 construct, were lysed 
and fractionated according to Dou et al.77  Nuclear fractions were combined with 
concentrations of MM-102 at 0.2, 2.0 and 20 μM and immunoprecipitated using M2 
agarose as described.77  WDR5, RbBP5 and MLL1C were detected by western blotting. 
12) Inhibition of H3K4 Methyltransferase Activity of the MLL1 Core Complex (by 
Elizabeth C. Townsend) 
a) Protein Expression 
MLL13762-C’, WDR523-C’, RbBP5 and ASH2LSPRY were expressed as His-SUMO 
fusions from the pET28A-SUMO vector (expression vectors were a generous gift from 
the Lei Lab). Proteins were expressed from BL21 DE3 pLyss codon (+) at 16 C 
overnight after induction with 0.1 mM IPTG in mid-log phase of bacterial growth.  Cells 
were harvested and protein was purified by the His-tag on Ni-NTA resin (Qiagen) as 
described previously.  The SUMO tag was removed from RbBP5, ASH2L and MLL1 by 
incubation with the ULP1 protease at 4 C overnight.  The protease and cleaved SUMO-
His tag were collected by batch binding with the Ni-NTA resin for 1h.  
b) In vitro Methyltransferase Assay 
Assays were performed in 50 mM HEPES pH 7.8, 100 mM NaCl, 1.0 mM EDTA 
and 5% glycerol at room temperature (approximately 22 C). Each reaction contained 1.5 
Ci of the co-factor, 3H-S-adenosyl methionine (Perkin Elmer).  H3 10mer was used as 
the substrate at 50 M.  Inhibitors were added at concentrations ranging from 0.125-128 
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M and incubated with the pre-assembled WDR5, RbBP5, ASH2L complex at a final 
concentration of 0.5 M. 3-component complex for 2-5 min.  Reactions were initiated by 
addition of the MLL13762-C’ fragment at a final concentration of 0.5 M and allowed to 
proceed for 30 min before preparing for scintillation counting. To count samples, 
reactions were spotted on separate squares of P81 filter paper (Whatman) and precipitated 
by submerging in freshly prepared 50 mM sodium bicarbonate buffer, pH 9.0.  After 
washing and drying, samples were vortexed in Ultima Gold scintillation fluid and 
counted.  As a negative control, assays were performed using 0.5 M MLL1 complex 
assembled with the non-interacting mutant, WDR5D107A. 
13) Inhibition of MLL1 Target Gene Expression (by Fang Cao, Ph.D.) 
qRT-PCR Analysis of HoxA9 and Meis-1 Genes 
Total RNA was isolated from MLL1-AF9 transduced cells using RNEASY® from 
QIAGEN 1 µg of total RNA was treated with RNase-free DNase I, and applied for 
reverse transcription using SuperScript III First-Strand Synthesis system (Invitrogen, 
Cat18080-051) according to manufacturer's protocol. The resulting cDNA was used as 
template for PCR amplification of HoxA9 genes using SYBR PCR kit (Applied 
Biosystem).  
HoxA9-F: ccgggttattgggatcgat, 
HoxA9-R:gcgccttctccgaaaaca,   
Meis-1-F:  aaggtgatggcttggacaac,  
Meis-1 R: tgtgccaactgctttttctg 
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14) Inhibition of Cell Growth (by Fang Cao, Ph.D.) 
CellTiter-Glo® Luminescent Cell Viability Assay 
MV4:11, KOPN8, and K562 cells were cultured in RPMI 1640 medium (ATCC) 
supplemented with 10% fetal bovine serum, 100 U/L penicillin-streptomycin, and 
incubated at 37 °C under 5% CO2.  Cells were seeded into 12-well plates for suspension 
at a density of 5×105 per well (1ml) and treated with the following: vehicle control 
(DMSO), MM-102 for 2, 4, or 7 days. Cells were given fresh medium with each 
application of the compound every two days. 
The CellTiter-Glo® Luminescent Cell Viability Assay kit (Promega) was used 
following the manufacturer's instruction. 100 µl of the assay reagent was added into each 
well and the content was mixed for 2 min on an orbital shaker to induce cell lysis. After 
10 min incubation in room temperature, the luminescence was read on a Microplate 
Reader (SpectraMax M5, Molecular Devices).  
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Appendix B 
Spectral Data 
Spectral data for the compounds designed in the study are shown in Table 16 and 
Table 17.  
Table 16: ESI-Mass characterization and HPLC analysis of the compounds in Chapters 2 and 3. 
 
Peptide 
 
% Purity 
(analytical RP-
HPLC) * 
 
Calculated
 
Observed 
(ESI-MS)** 
(M+2H)2+ 
 
WIN-FAM-1 
 
> 99 
 
1026.009 
 
1026.20 
 
WIN-FAM-2 
 
99 
 
1032.538 
 
1032.60 
 (M+H)+ 
 
10mer-Ala-FAM 
 
98 
 
1920.013 
 
1919.87 
 
10mer-Thr-FAM 
 
 99 
 
1950.024 
 
1949.87 
 
WIN 
 
95 
 
1351.756 
 
1351.73 
 
Ac-11mer 
 
> 99 
 
1294.734 
 
1294.80 
 
Ac-10mer 
 
90 
 
1207.702 
 
1207.73 
 
NH2-11mer 
 
> 99 
 
1252.724 
 
1252.80 
 
Ac- 9mer 
 
98 
 
1136.665 
 
1136.73 
 
Ac-7mer 
 
96 
 
836.474 
 
836.53 
 
Ac-6mer 
 
97 
 
723.390 
 
723.53 
 
Ac-5mer 
 
99 
 
586.331 
 
586.47 
 
Ac-4mer 
 
93 
 
487.263 
 
487.40 
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Ac-3mer (ARA) 
 
96 
 
358.220 
 
358.33 
 
Ac-2mer  
 
> 99 
 
287.183 
 
287.27 
 
NH2-10mer 
 
98 
 
1165.692 
 
1165.73 
 
NH2-3mer 
 
> 99 
 
316.210 
 
316.27 
 
CHO-ARA 
 
> 99 
 
344.205 
 
344.27 
 
Δ1 
 
> 99 
 
372.236 
 
372.33 
 
Δ2a 
 
95 
 
372.236 
 
372.33 
 
Δ2b 
 
> 99 
 
386.252 
 
386.33 
 
Δ2c 
 
95 
 
373.220 
 
373.33 
 
H3-10mer 
 
> 99 
 
1145.687 
 
1145.80 
 
Ac-H3-10mer 
 
> 99 
 
1187.697 
 
1187.73 
 
H3-3mer 
 
93 
 
346.220 
 
346.27 
 
Ac-H3-3mer 
 
95 
 
388.231 
 
388.33 
 
H3-10mer-K4Me 
 
> 99 
 
1159.702 
 
1159.80 
 
H3-10mer-K4Me2 
 
> 99 
 
1173.718 
 
1173.80 
 
H3-10mer-K4Me3 
 
> 99 
 
1188.741 
 
1187.80 
* Waters, SunfireTM C18, 4.6×150mm, 5µm. 
** Finnigan LCQ Deca (Thermoquest). 
 
 
 
 
 
 
81 
 
Peptide Calculated (M+H)+ 
Observed 
(M+H)+ 
ESI-MS)* 
1H-NMR** Chemical Shifts 
(D2O) 
1a 344.20 344.33 
4.39 (dd, J1= 5.6 Hz, J2= 8.1 Hz, 1H), 4.34 (q, 
J= 7.3 Hz, 1H), 3.96 (s, 2H), 3.25 (t, J= 6.8 Hz, 
2H), 2.09 (s, 3H), 1.98-1.61 (m, 4H), 1.44 (d, 
J= 7.3 Hz, 3H). 
1b 372.24 372.33 
4.43-4.27 (m, 2H), 4.17 (t, J= 7.1 Hz, 1H), 3.25 
(t, J= 6.5 Hz, 2H), 2.06 (s, 3H), 1.99-1.62 (m, 
6H), 1.43 (d, J= 7.3 Hz, 3H), 0.98 (t, J= 7.4 Hz, 
3H). 
1c 386.25 386.42 
4.44-4.28 (m, 2H), 4.08 (d, J= 7.4 Hz, 1H), 3.25 
(t, J= 6.7 Hz, 2H), 2.12-2.03 (m, 4H), 1.97-1.76 
(m, 2H), 1.75-1.61 (m, 2H), 1.43 (d, J= 7.2 Hz, 
3H), 0.98 (m, 6H). 
1d 390.19 390.33 
4.45 (t, J= 6.3 Hz, 1H), 4.40-4.33 (m, 1H), 4.28 
(q, J= 7.2 Hz, 1H), 3.20 (t, J= 6.7 Hz, 2H), 2.89 
(d, J= 6.3 Hz, 2H), 2.04 (s, 3H), 1.96-1.57 (m, 
4H), 1.39 (d, J= 7.2 Hz, 3H).  
1e 400.27 400.42 
4.42-4.26 (m, 3H), 3.24 (t, J= 6.6 Hz, 2H), 2.05 
(s, 3H), 1.97-1.51 (m, 7H), 1.42 (d, J= 7.1 Hz, 
3H), 0.97 (d, J= 5.8 Hz, 3H), 0.92 (d, J= 5.8 Hz, 
3H). 
1f 426.28 426.42 
4.40 (dd, J1= 5.7 Hz, J2= 8.3 Hz, 1H), 4.32 (q, 
J= 7.2 Hz, 1H), 4.09 (d, J= 7.7 Hz, 1H), 3.24 (t, 
J= 6.9 Hz, 2H), 2.06 (s, 3H), 1.95-1.54 (m, 9H), 
1.43 (d, J= 7.2 Hz, 3H), 1.31-0.99 (m, 6H). 
1g 424.24 424.42 
8.66 (s, 1H), 7.33 (s, 1H), 4.68 (t, J= 7.2 Hz, 
1H), 4.41-4.25 (m, 2H), 3.32-3.10 (m, 4H), 
2.02 (s, 3H), 1.93-1.58 (m, 4H), 1.43 (d, J= 7.2 
Hz, 3H). 
1h 434.25 434.42 
7.40-7.20 (m, 5H), 4.50 (t, J= 7.7 Hz, 1H), 
4.28-4.11 (m, 2H), 3.14 (t, J= 6.8 Hz, 2H), 
3.07-2.98 (m, 2H), 1.96 (s, 3H), 1.83-1.60 (m, 
2H), 1.59-1.44 (m, 2H), 1.38 (d, J= 7.2 Hz, 
3H). 
Table 17: ESI-Mass characterization and 1H-NMR spectra of the compounds in Chapter 4. 
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1i 374.22 374.33 
4.43-4.34 (m, 2H), 4.27 (q, J= 7.3 Hz, 1H), 
3.89-3.78 (m, 2H), 3.20 (t, J= 6.7 Hz, 2H), 2.05 
(s, 3H), 1.97-1.57 (m, 4H), 1.38 (d, J= 7.3 Hz, 
3H). 
1j 388.23 388.33 
 
4.46-4.14 (m, 4H), 3.25 (t, J= 6.7 Hz, 2H), 
2.19-1.62 (m, 7H), 1.43 (d, J= 7.3 Hz, 3H), 1.25 
(d, J= 6.3 Hz, 3H). 
2a 315.20 315.08 
 
4.38-4.25 (m, 3H), 2.05 (s, 3H), 1.92-1.68 (m, 
4H), 1.47-1.29 (m, 8H), 0.92 (t, J= 6.3 Hz, 3H). 
2b 316.20 316.17 
4.45-4.23 (m, 3H), 3.06 (t, J= 6.8 Hz, 2H), 2.05 
(s, 3H), 2.01-2.69 (m, 4H), 1.48-1.35 (m, 6H). 
2c 330.21 330.25 
4.41-4.24 (m, 3H), 3.04 (t, J= 7.3 Hz, 2H), 2.05 
(s, 3H), 1.96-1.65 (m, 4H), 1.57-1.35 (m, 8H). 
2d 359.20 359.08 
4.39-4.24 (m, 3H), 3.15 (t, J= 6.6 Hz, 2H), 2.04 
(s, 3H), 1.95-1.67 (m, 2H), 1.66-1.50 (m, 2H), 
1.46-1.35 (m, 6H). 
3a 344.20 344.33 
 
4.32 (dd, J1= 5.8Hz, J2= 8.3 Hz, 1H), 4.25 (q, 
J= 7.2 Hz, 1H), 3.90 (d, J= 4.0 Hz, 2H), 3.20 (t, 
J= 6.7 Hz, 2H), 2.00 (s, 3H), 1.96-1.53 (m, 4H), 
1.35 (d, J= 7.2 Hz, 3H). 
3b 372.24 372.33 
 
4.39 (t, J= 7.0 Hz, 1H), 4.34-4.18 (m, 2H), 3.25 
(t, J= 6.7 Hz, 2H), 2.07-1.57 (m, 9H), 1.40 (d, 
J= 7.2 Hz, 3H), 0.98 (t, J= 7.4 Hz, 3H). 
3c 386.25 386.42 
 
4.41 (t, J= 7.1 Hz, 1H), 4.29 (q, J= 7.2 Hz, 1H), 
4.14 (d, J= 7.5 Hz, 1H), 3.25 (t, J= 6.7 Hz, 2H), 
2.15-1.96 (m, 4H), 1.94-1.54 (m, 4H), 1.39 (d, 
J= 7.2 Hz, 3H), 0.99 (d, J= 6.6 Hz, 6H). 
3d 390.19 390.33 
 
4.53-4.47 (m, 1H), 4.41-4.34 (m, 1H), 4.26 (q, 
J= 7.2 Hz, 1H), 3.22 (t, J= 6.8 Hz, 2H), 3.01-
2.85 (m, 2H), 2.01 (s, 3H), 1.94-1.59 (m, 4H), 
1.37 (d, J= 7.2 Hz, 3H). 
3e 400.27 400.42 
 
 
4.43 (m, 3H), 3.25 (t, J= 6.7 Hz, 2H), 2.05 (s, 
3H), 1.98-1.54 (m, 7H), 1.39 (d, J= 7.2 Hz, 
3H), 0.97 (d, J= 4.4 Hz, 3H), 0.91 (d, J= 5.13 
Hz, 3H). 
3f 426.28 426.42 
 
 
4.40 (t, J= 7.0 Hz, 1H), 4.29 (q, J= 7.2 Hz, 1H), 
4.17 (d, J= 7.5 Hz, 1H), 3.25 (t, J= 6.8 Hz, 2H), 
2.07-1.54 (m, 13H), 1.43-0.95 (m, 8H). 
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3g 434.25 434.42 
 
 
7.45 (m, 5H), 4.67 (dd, J1= 6.0 Hz, J2= 9.0 Hz, 
1H), 4.32-4.20 (m, 2H), 3.25 (dd, J1= 5.9 Hz, 
J2= 14.0 Hz, 1H), 3.16 (t, J= 6.9 Hz, 2H), 3.03 
(dd, J1= 9.3 Hz, J2= 14 Hz, 1H), 2.05 (s, 3H), 
1.77-1.62 (m, 2H), 1.56-1.40 (m, 2H), 1.34 (d, 
J= 7.2 Hz, 3H). 
3h 374.22 374.33 
 
4.49-4.39 (m, 2H), 4.30 (q, J= 7.2 Hz, 1H), 
3.93-3.85 (m, 2H), 3.26 (t, J= 6.6 Hz, 2H), 
2.07-1.62 (m, 7H), 1.41 (d, J= 7.2 Hz, 3H). 
3i 388.23 388.33 
 
4.46 (dd, J1= 5.6 Hz, J2= 8.5 Hz, 1H), 4.38-4.23 
(m, 3H), 3.26 (t, J= 6.7 Hz, 2H), 2.09-1.61 (m, 
7H), 1.41 (d, J= 7.2 Hz, 3H), 1.24 (d, J= 6.3 Hz, 
3H). 
3j 416.23 416.42 
 
4.43-4.24 (m, 3H), 3.25 (t, J= 6.7 Hz, 2H), 2.51 
(t, J= 7.1 Hz, 2H), 2.23-1.61 (m, 9H), 1.39 (d, 
J= 7.2 Hz, 3H). 
4a 398.25 398.20 
4.44 (dd, J1= 5.9 Hz, J2= 8.5 Hz, 1H), 4.13 (d, 
J= 7.4 Hz, 1H), 3.24 (t, J= 6.8 Hz, 2H), 2.16-
2.04 (m, 4H), 1.98-1.51 (m, 5H), 1.49-1.40 (m, 
1H), 1.26-1.11 (m, 2H), 0.99 (d, J= 6.7 Hz, 
6H). 
4b 412.27 412.20 
4.42 (dd, J1= 5.5 Hz, J2= 8.6 Hz, 1H), 4.14 (d, 
J= 7.3 Hz, 1H), 3.23 (t, J= 6.8 Hz, 2H), 2.73-
2.50 (m, 2H), 2.32-1.55 (m, 12H), 1.00 (d, J= 
6.7 Hz, 6H). 
4c 426.28 426.24 
4.43-4.35 (m, 1H), 4.13 (d, J= 7.2 Hz, 1H), 3.23 
(t, J= 6.5 Hz, 2H), 2.29-1.54 (m, 16H), 0.99 (d, 
J= 6.6 Hz, 6H). 
4d 440.30 440.24 
4.43-4.35 (m, 1H), 4.13 (d, J= 7.3 Hz, 1H), 3.24 
(t, J= 6.7 Hz, 2H), 2.20-1.41 (m, 17H), 1.40-
1.21 (m, 1H), 1.00 (d, J= 6.7 Hz, 6H). 
4e 400.27 400.20 
4.42-4.34 (m, 1H), 4.12 (d, J= 7.2 Hz, 1H), 3.24 
(t, J= 6.7 Hz, 2H), 2.20-2.06 (m, 1H), 2.02 (s, 
3H), 1.98-1.56 (m, 4H), 1.47 (s, 6H), 1.00 (d, 
J= 6.7 Hz, 6H). 
4f 428.30 428.42 
4.42 (dd, J1= 5.5 Hz, J2= 8.8 Hz, 1H), 4.11 (d, 
J= 7.5 Hz, 1H), 3.24 (t, J= 6.8 Hz, 2H) 2.20-
1.55 (m, 12H), 1.00 (d, J= 6.8 Hz, 6H), 0.81 (t, 
J= 7.4 Hz, 6H). 
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4g 428.30 428.24 
4.46 (t, J= 7.0 Hz, 1H), 4.17-4.10 (m, 2H), 3.24 
(t, J= 6.5 Hz, 2H), 2.16-2.02 (m, 4H), 1.93-1.55 
(m, 4H), 1.08-0.95 (m, 15H). 
4h 414.28 414.24 
4.45 (dd, J1= 6.0 Hz, J2= 8.2 Hz, 1H), 4.25 (t, 
J= 7.2 Hz, 1H), 4.14 (d, J= 7.4 Hz, 1H), 3.25 (t, 
J= 6.8 Hz, 2H), 2.16-2.02 (m, 4H), 1.96-1.57 
(m, 6H), 1.49-1.29 (m, 2H), 0.99 (dd, J1= 2.4 
Hz, J2= 6.8 Hz, 3H), 0.94 (t, J= 7.4 Hz, 3H). 
4i 440.30 440.24 
4.46 (t, J= 7.1 Hz, 1H), 4.13 (d, J= 7.5 Hz, 1H), 
4.07 (d, J= 9.3 Hz, 1H), 3.25 (t, J= 6.8 Hz, 2H), 
2.24-2.02 (m, 5H), 1.95-1.51 (m, 10H), 1.42-
1.23 (m, 2H), 0.99 (d, J= 6.6 Hz, 6H). 
4j 448.27 448.33 
7.52-7.44 (m, 5H), 5.39 (s, 1H), 4.46 (dd, J1= 
6.0 Hz, J2= 8.5 Hz, 1H), 4.05 (d, J= 7.2 Hz, 
1H), 3.22 (t, J= 6.9 Hz, 2H), 2.10 (s, 3H), 2.06-
1.95 (m, 1H), 1.94-1.72 (m, 2H), 1.71-1.53 (m, 
2H), 0.88 (d, J= 6.8 Hz, 3H), 0.83 (d, J= 6.8 Hz, 
3H). 
4k 448.27 448.42 
7.53-7.44 (m, 5H), 5.39 (s, 1H), 4.42 (dd, J1= 
5.3 Hz, J2= 9.3 Hz, 1H), 4.14 (d, J= 7.3 Hz, 
1H), 3.07 (t, J= 7.1 Hz, 2H), 2.17-2.01 (m, 4H), 
1.93-1.65 (m, 2H), 1.50-1.33 (m, 2H), 0.97 (d, 
J= 6.8 Hz, 3H), 0.96 (d, J= 6.8 Hz, 3H). 
5a 398.25 398.33 
4.19 (t, J= 7.0 Hz, 1H), 4.10 (d, J= 7.2 Hz, 1H), 
3.25 (t, J= 6.7 Hz, 2H), 2.16-2.03 (m, J= 4H), 
1.91-1.42 (m, 6H), 1.22-1.10 (m, 2H), 1.04-
0.93 (m, 6H). 
5b 412.27 412.33 
4.28 (t, J= 7.2 Hz, 1H), 4.02 (d, J= 7.3 Hz, 1H), 
3.22 (t, J= 6.6 Hz, 2H), 2.69-2.49 (m, J= 2H), 
2.25-1.91 (m, 8H), 1.87-1.53 (m, 4H), 0.98-
0.89 (m, 6H). 
5c 426.28 426.33 
4.35 (t, J= 7.1 Hz, 1H), 4.07 (d, J= 7.3 Hz, 1H), 
3.25 (t, J=6.6 Hz, 2H), 2.31-1.54 (m, 16H), 
1.03-0.93 (m, 6H). 
5d 440.30 440.42 
4.43 (t, J= 7.1 Hz, 1H), 4.08 (d, J= 7.5 Hz, 1H), 
3.26 (t, J= 6.7 Hz, 2H), 2.22-1.28 (m, 18H), 
1.05-0.92 (m, 6H). 
5e 400.27 400.33 
4.33 (t, J= 7.0 Hz, 1H), 4.07 (d, J= 7.3 Hz, 1H), 
3.25 (t, J= 6.6 Hz, 2H), 2.14-2.01 (m, 4H), 
1.94-1.56 (m, 4H), 1.50 (s, 6H), 1.04-0.92 (m, 
6H). 
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5f 428.30 428.42 
4.46 (t, J= 7.1 Hz, 1H), 4.13 (s, 1H), 4.03 (d, J= 
7.6 Hz, 1H), 3.19 (t, J= 6.6 Hz, 2H), 2.09-1.93 
(m, 4H), 1.89-1.48 (m, 4H), 0.99 (s, 9H), 0.96-
0.88 (m, 6H). 
5g 440.30 440.42 
4.46 (t, J= 7.0 Hz, 1H), 4.13 (d, J= 9.3 Hz, 1H), 
4.08 (d, J= 7.4 Hz, 1H), 3.24 (t, J= 6.7 Hz, 2H), 
2.32-2.15 (m, 1H), 2.13-1.99 (m, 4H), 1.95-
1.52 (m, 10H), 1.43-1.20 (m, 2H), 1.04-0.91 
(m, 6H). 
6a 386.25 386.33 
4.36 (dd, J1= 5.4 Hz, J2= 8.9 Hz, 1H), 4.20 (t, 
J= 7.1 Hz, 1H), 2.25 (t, J= 6.7 Hz, 2H), 2.03 (s, 
3H), 2.01-1.58 (m, 6H), 1.48 (s, 6H), 0.99 (t, 
7.4 Hz). 
6b 412.27 412.33 
4.31-4.24 (m, 1H), 3.25 (t, J= 6.7 Hz, 2H), 
2.26-2.10 (m, 2H), 2.07-2.54 (m, 13H), 1.48 (s, 
6H). 
6c 402.25 402.42 
4.43 (dd, J1= 5.0 Hz, J2= 9.2 Hz, 1H), 4.37-4.26 
(m, 2H), 3.25 (t, J= 6.8 Hz, 2H), 2.03 (s, 3H), 
2.00-1.58 (m, 4H), 1.49 (s, 6H), 1.25 (d, J= 6.1 
Hz, 3H). 
6d 398.25 398.33 
4.33(dd, J1= 5.4 Hz, J2= 8.9 Hz, 1H), 4.19-4.11 
(m, 1H), 3.18 (t, J= 6.7 Hz, 2H), 2.66-2.46 (m, 
2H), 2.25-1.49 (m, 13H), 0.93 (t, J= 7.3 Hz, 
3H). 
6e 424.27 424.42 
4.25 (dd, J1= 5.8 Hz, J2= 8.6 Hz, 1H), 3.19 (t, 
J= 6.8 Hz, 2H), 2.65-2.47 (m, 2H), 2.25-1.49 
(m, 19H).  
6f 414.25 414.33 
4.45 (dd, J1= 5.1 Hz, J2= 9.3 Hz, 1H), 4.36-4.25 
(m, 2H), 3.24 (t, J= 6.9 Hz, 2H), 2.74-2.52 (m, 
2H), 2.32-1.87 (m, 8H), 1.86-1.73 (m, 1H), 
1.72-1.56 (m, 2H), 1.24 (d, J= 6.3 Hz, 3H). 
6g 440.30 440.41 
4.28-4.17 (m, 1H), 3.13 (t, J= 6.6 Hz, 2H), 
2.25-1.43 (m, 19H), 0.76 (t, J= 7.3 Hz, 6H). 
7a 386.25  386.31  
4.41-4.24 (m, 3H), 3.25 (t, J= 6.7 Hz, 2H), 
2.65-2.50 (m, 1H), 1.96- 1.62 (m, 4H), 1.43 (d, 
J= 7.3 Hz, 3H), 1.40 (d, J= 7.3 Hz, 3H), 1.12 (d, 
J= 6.9 Hz, 6H). 
7b 384.24  384.30  
4.40-4.26 (m, 3H), 3.25 (t, J= 6.8 Hz, 2H), 
1.97-1.61 (m, 5H), 1.45-1.39 (m, 6H), 0.94-
0.83 (m, 4H). 
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7c 398.25  398.33  
4.41-4.24 (m, 3H), 3.29-3.16 (m, 3H), 2.25-
1.16 (m, 10H), 1.44 (d, J= 7.1Hz, 3H), 1.39 (d, 
J= 6.8 Hz, 3H). 
7d 386.25  386.42  
4.40-4.26 (m, 3H), 3.25 (t, J= 6.6 Hz, 2H), 2.28 
(t, J= 7.1 Hz, 2H) 1.96-1.56 (m, 6H), 1.46-1.37 
(m, 6H), 0.93 (t, J= 7.4 Hz, 3H). 
7e 400.27  400.34  
4.41-4.26 (m, 3H), 3.25 (t, J= 6.5 Hz, 2H), 2.31 
(t, J= 7.3 Hz, 2H), 1.97-1.53 (m, 6H), 1.46-1.26 
(m, 8H), 0.92 (t, J= 7.3 Hz, 3H). 
7f 400.27  400.35  
4.40-4.28 (m, 3H), 3.25 (t, J= 6.5 Hz, 2H), 2.18 
(d, J= 7.7 Hz, 2H), 2.07-1.62 (m, 5H), 1.47-
1.37 (m, 6H), 0.95 (d, J= 6.5 Hz, 6H). 
7g 420.24  420.32  
7.83 (d, J=7.9 Hz, 2H), 7.67 (m, 1H), 7.57 (m, 
2H), 4.53(q, J= 7.1 Hz, 1H), 4.41 (t, J= 6.7 Hz, 
1H), 4.33 (q, J= 7.2 Hz, 1H), 3.24 (t, J= 6.7 Hz, 
2H), 1.99-1.64 (m, 4H), 1.53 (d, J= 7.1 Hz, 
3H), 1.43 (d, J= 7.2 Hz, 3H). 
7h 434.25  434.34  
7.48-7.33 (m, 5H), 4.37-4.25 (m, 3H), 3.67 (s, 
2H), 3.18 (t, J= 6.8 Hz, 2H), 1.87-1.62 (m, 4H), 
1.41 (d, J= 7.2 Hz, 3H), 1.38 (d, J= 7.3 Hz, 3H).
7i 426.28  426.36  
4.41-4.27 (m, 3H), 3.25 (t, J= 6.4 Hz, 2H), 2.30 
(d, J= 7.2 Hz, 2H), 2.23-2.10 (m, 1H), 1.97-
1.51 (m, 10H), 1.46-1.37 (m, 6H), 1.26-1.12 
(m, 2H). 
7j 373.23  373.33 
4.41-4.27 (m, 2H), 4.16 (q, J= 7.0 Hz, 1H), 3.25 
(t, J= 6.5 Hz, 2H), 2.71 (s, 3H), 2.00-1.63 (m, 
4H), 1.44 (d, J= 7.0 Hz, 3H), 1.37 (d, J= 7.0 Hz, 
3H). 
7k 387.25 387.75 
4.39-4.28 (m, 2H), 4.18 (q, J= 7.3 Hz, 1H), 3.25 
(t, J= 6.6 Hz, 2H), 2.94 (s, 6H), 1.98-1.63 (m, 
4H), 1.44 (d, J=7.3 Hz, 3H), 1.40 (d, J= 7.3 Hz, 
3H). 
8a 372.24 372.33 
4.40-4.23 (m, 3H), 3.25 (t, J= 6.6 Hz, 2H), 2.77 
(s, 3H), 2.05 (s, 3H), 1.97-1.59 (m, 4H), 1.39 
(d, J= 7.0 Hz, 6H). 
8b 400.27  400.42  
4.29-4.09 (m, 3H), 3.91-3.77 (m, 1H), 3.16 (t, 
J= 6.6 Hz, 2H), 1.96 (s, 3H), 1.87-1.53 (m, 4H), 
1.30 (d, J=6.3, 6H), 1.10-1.03 (m, 6H). 
8c 428.30  428.42  
4.38-4.25 (m, 3H), 3.66-3.55 (m, 1H), 3.25 (t, 
J= 6.5, 2H), 2.05 (s, 3H), 1.96-1.52 (m, 6H), 
1.46-1.37 (m, 8H), 0.87 (t, J= 7.3 Hz, 6H). 
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8d 440.30  440.42  
 
4.38-4.21 (m, 3H), 3.66-3.55 (m, 1H), 3.25 (t, 
J= 6.7 Hz, 2H), 2.05 (s, 3H), 1.94-1.58 (m, 9H), 
1.41-1.14 (m, 11H). 
8e 343.25  434.33  
7.50-7.44 (m, 4H), 7.36-7.27 (m, 1H), 4.51-
4.25 (m, 3H), 3.23 (t, J= 6.6 Hz, 2H), 2.05 (s, 
3H), 1.97-1.6 (m, 4H), 1.52 (d, J= 6.7 Hz, 3H), 
1.39 (d, 6.9 Hz, 3H). 
8f 448.27  448.42  
7.47-7.31 (m, 5H), 4.50-4.22 (m, 5H), 3.17 (t, 
J= 6.6 Hz, 2H), 2.04 (s, 3H), 1.93-1.54 (m, 4H), 
1.43 (d, J= 7.0 Hz, 3H), 1.37 (d, J= 7.0 Hz, 3H).
8g 524.30  524.42  
7.48-7.31 (m, 10H), 6.09 (s, 1H), 4.48-4.20 (m, 
3H), 3.12 (t, J= 6.5 Hz, 2H), 2.04 (s, 3H), 1.89-
1.50 (m, 4H), 1.44 (d, J=7.1 Hz, 3H), 1.36 (d, 
J= 7.2 Hz, 3H). 
MM-101 
(MeOD) 
634.41 634.49 
7.42-7.21 (m, 10H), 6.21 (s, 1H), 4.04-3.98 (m, 
1H), 3.21 (t, J= 7.0 Hz, 2H), 2.56-2.46 (m, 1H), 
2.37-2.09 (m, 4H), 1.94-1.59 (m, 12H), 1.14-
1.05 (m, 6H), 0.84-0.71 (m, 6H). 
MM-102 
(MeOD) 
670.39 670.33 
7.41-7.28 (m, 4H), 7.07-6.96 (m, 4H), 6.17 (s, 
1H), 3.95-3.88 (m, 1H), 3.23-3.16 (m, 2H), 
2.55-2.43 (m, 1H), 2.37-2.01 (m, 4H), 1.94-
1.52 (m, 12H), 1.07 (dd, J1= 5.3 Hz, J2= 6.7 Hz 
6H), 0.79-0.68 (m, 6H). 
* Thermo Scientific LCQ Fleet  
** Bruker 300 MHz 
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